Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press147410.36691/RJA1474Clinical practice guidelinesКлинические рекомендацииReview ArticleAtopic dermatitisАтопический дерматитhttps://orcid.org/0000-0002-7625-05038771-4990KubanovAlexey A.КубановАлексей Алексеевич
Russian Federation

MD, Dr. Sci. (Med.), Senior Research Associate

д.м.н., профессор, член-корреспондент РАН

alex@cnikvi.ruhttps://orcid.org/0000-0002-2209-75311312-2147Namazova-BaranovaLeyla S.Намазова-БарановаЛейла Сеймуровна
Russian Federation

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

д.м.н., профессор, академик РАН

leyla.s.namazova@gmail.comhttps://orcid.org/0000-0003-1829-0424KhaitovRakhim M.ХаитовРахим Мусаевич
Russian Federation

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

д.м.н., профессор, академик РАН

rm.khaitov@nrcii.ruhttps://orcid.org/0000-0002-3556-969X6715-5650IlyinaNatalya I.ИльинаНаталья Ивановна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

instimmun@yandex.ruhttps://orcid.org/0000-0002-8023-25437253-7970AlekseevaAnna A.АлексееваАнна Александровна
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

aleksaa06@yandex.ruhttps://orcid.org/0000-0002-8232-89364878-5562AmbarchianEduard T.АмбарчянЭдуард Тигранович
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

edo_amb@mail.ruhttps://orcid.org/0000-0002-2793-88622627-9842ArtemyevaSofya I.АртемьеваСофья Иосифовна
Russian Federation
sofya.chern@gmail.comhttps://orcid.org/0000-0003-2952-90821821-9471ArshinskiyMark I.АршинскийМарк Иванович
Russian Federation
kkvd80@inbox.ruhttps://orcid.org/0000-0002-7691-45849941-7013AstafyevaNatalia G.АстафьеваНаталья Григорьевна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

astang@mail.ruhttps://orcid.org/0000-0001-7398-05621109-2810VishnevaElena A.ВишневаЕлена Александровна
Russian Federation

MD, Dr. Sci. (Med)

д.м.н.

vishneva.e@yandex.ruhttps://orcid.org/0000-0002-8363-51888206-2731VolnukhinVladimir A.ВолнухинВладимир Анатольевич
Russian Federation

MD, Dr. Sci (Med), Professor

д.м.н., профессор

vvoln@rambler.ruhttps://orcid.org/0000-0002-8279-21734547-3948DanilychevaInna V.ДанилычеваИнна Владимировна
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

ivdanilycheva@mail.ruhttps://orcid.org/0000-0002-4609-25919567-1894ElisyutinaOlga G.ЕлисютинаОльга Гурьевна
Russian Federation

MD, Dr. Sci. (Med.), Senior Research Associate

д.м.н., в.н.с.

olga@yandex.ruhttps://orcid.org/0000-0002-4107-46425162-7846EpishevRoman V.ЕпишевРоман Владимирович
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

drepishev@gmail.comhttps://orcid.org/0000-0002-3960-830X2765-9617ZhestkovAleksandr V.ЖестковАлександ Викторович
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

avzhestkov2015@yandex.ruhttps://orcid.org/0000-0003-2545-21298930-4073ZhilovaMaryana B.ЖиловаМарьяна Борисовна
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н.

zhilova@cnikvi.ruhttps://orcid.org/0000-0001-5723-65738584-7564ZhukovaOlga V.ЖуковаОльга Валентиновна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

klinderma@inbox.ruhttps://orcid.org/0000-0001-5936-62325832-9510ZaslavskyDenis V.ЗаславскийДенис Владимирович
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

venerology@gmail.comhttps://orcid.org/0000-0002-2553-04849552-7850ZnamenskayaLyudmila F.ЗнаменскаяЛюдмила Федоровна
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н.

znaml@cnikvi.ruhttps://orcid.org/0000-0003-3805-84893604-6491KaramovaArfenya E.КарамоваАрфеня Эдуардовна
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

karamova@cnikvi.ruhttps://orcid.org/0000-0002-0913-000X7319-7942KorotkyNikolay G.КороткийНиколай Гаврилович
Russian Federation

MD, Dr. Sci (Med.), Professor

д.м.н., профессор

kng40@mail.ruhttps://orcid.org/0000-0001-6353-66443470-9306KokhanMuza M.КоханМуза Михайловна
Russian Federation

MD, Dr. Sci (Med.), Professor

д.м.н., профессор

mkokhan@yandex.ruhttps://orcid.org/0000-0002-5044-52651107-4372KruglovaLarisa S.КругловаЛариса Сергеевна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

kruglovals@mail.ruhttps://orcid.org/0000-0002-4134-047X3903-2425KungurovNikolay V.КунгуровНиколай Васильевич
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

N.kungurov@gmail.comhttps://orcid.org/0000-0002-2460-77184626-2800LevinaJulia G.ЛевинаЮлия Григорьевна
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

julia.levina@mail.ruhttps://orcid.org/0000-0002-3875-40301053-3290LvovAndrey N.ЛьвовАндрей Николаевич
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

alvov@mail.ruhttps://orcid.org/0000-0002-6034-82315935-8090MaterikinAlexander I.МатерикинАлександр Игоревич
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

al_m86@bk.ruhttps://orcid.org/0000-0002-6415-4338MishinaOlesya S.МишинаОлеся Сергеевна
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

olesya.mishina@mail.ruhttps://orcid.org/0000-0002-8211-16651837-2098MonakhovKonstantin N.МонаховКонстанти Николаевич
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

knmonakhov@gmail.comhttps://orcid.org/0000-0003-2252-85705906-9724MurashkinNikolay N.МурашкинНиколай Николаевич
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н.

m_nn2001@mail.ruhttps://orcid.org/0000-0002-3162-25103363-6170NenashevaNatalia M.НенашеваНаталья Михайловна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

1444031@gmail.comhttps://orcid.org/0000-0001-5039-84739722-7961PampuraAlexander N.ПампураАлександр Николаевич
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

apampura1@mail.ruhttps://orcid.org/0000-0003-4169-41287634-5521PlakhovaXenia I.ПлаховаКсения Ильинична
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н.

plahova@cnikvi.ruhttps://orcid.org/0000-0002-9578-54908862-5688PotekaevNikolay N.ПотекаевНиколай Николаевич
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

klinderma@mail.ruhttps://orcid.org/0000-0001-6515-19242988-8463PrytulоOlga A.ПритулоОльга Александровна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

55550256@mail.ruhttps://orcid.org/0000-0003-1022-74634587-2393RaznatovskiyKonstantin I.РазнатовскийКонстантин Игоревич
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

konstantan.r@bk.ruhttps://orcid.org/0000-0001-9231-23911875-7155SapuntsovaSvetlana G.СапунцоваСветлана Геннадьевна
Russian Federation

MD, Cand. Sci. (Med.), Associate Professor

к.м.н., доцент

ssfesmu@yandex.ruhttps://orcid.org/0000-0002-3678-79395508-1689SelimzianovaLiliia R.СелимзяноваЛилия Робертовна
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

lilysir@mail.ruhttps://orcid.org/0000-0001-5793-57538649-6138SkorokhodkinaOlesya V.СкороходкинаОлеся Валерьевна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

olesya-27@rambler.ruhttps://orcid.org/0000-0003-3358-50875012-7242FedenkoElena S.ФеденкоЕлена Сергеевна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

efedks@gmail.comhttps://orcid.org/0000-0002-5083-66373023-4538FominaDaria S.ФоминаДарья Сергеевна
Russian Federation

MD, Associate Professor

к.м.н., доцент

daria_fomina@mail.ruhttps://orcid.org/0000-0001-6231-971X7009-9991FrigoNataliya V.ФригоНаталия Владиславовна
Russian Federation

MD, Dr. Sci. (Med)

д.м.н.

frigo2013@yandex.ruhttps://orcid.org/0000-0002-2633-14529490-7107FrolovaZoya V.ФроловаЗоя Вадимировна
Russian Federation
kkvd80@inbox.ruhttps://orcid.org/0000-0003-4961-96403199-9803KhaitovMusa R.ХаитовМуса Рахимович
Russian Federation

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

д.м.н., профессор, член-корреспондент РАН

mr.khaitov@nrcii.ruhttps://orcid.org/0000-0002-9688-27273385-4723ChikinVadim V.ЧикинВадим Викторович
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н.

chikin@cnikvi.ruState Research Center of Dermatovenerology and CosmetologyГосударственный научный центр дерматовенерологии и косметологииResearch Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of SciencesНаучно-исследовательский институт педиатрии и охраны здоровья детей ЦКБ РАНPirogov Russian National Research Medical UniversityРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаNational Research Center ― Institute of Immunology Federal Medical-Biological Agency of RussiaГосударственный научный центр «Институт иммунологии» Федерального медико-биологического агентстваState Autonomous Institution “National Medical Research Center of Children’s Health”Национальный медицинский исследовательский центр здоровья детейMoscow Scientific and Practical Center for Dermatovenereology and Cosmetology of the Moscow Healthcare DepartmentМосковский научно-практический центр дерматовенерологии и косметологииRegional Skin and Venereological DispensaryКраевой кожно-венерологический диспансерSaratov State Medical University named after V.I. RazumovskyСаратовский государственный медицинский университет имени В.И. РазумовскогоSamara State Medical UniversityСамарский государственный медицинский университетSaint Petersburg State Pediatric Medical UniversityСанкт-Петербургский государственный педиатрический медицинский университетUral Research Institute of Dermatovenereology and ImmunopathologyУральский научно-исследовательский институт дерматовенерологии и иммунопатологииCentral State Medical Academy of Department of Presidential AffairsЦентральная государственная медицинская академия Управления делами Президента Российской ФедерацииLomonosov Moscow State UniversityМедицинский научно-образовательный центр Московского государственного университета имени М.В. ЛомоносоваPavlov First Saint Petersburg State Medical UniversityПервый Санкт-Петербургский государственный медицинский университет имени академика И.П. ПавловаRussian Medical Academy of Continuous Professional EducationРоссийская медицинская академия непрерывного профессионального образованияVeltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical UniversityНаучно-исследовательский клинический институт педиатрии имени академика Ю.Е. Вельтищева ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова»S.I. Georgievsky Medical Academy of the Crimean Federal University named after V.I. VernadskyМедицинская академия имени С.И. Георгиевского ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского»North-Western State Medical University named after I.I. MechnikovСеверо-Западный государственный медицинский университет имени И.И. МечниковаThe Far-Eastern State Medical UniversityДальневосточный государственный медицинский университетKazan State Medical UniversityКазанский государственный медицинский университетСlinical State Hospital No. 52Городская больница № 52First Sechenov Moscow State Medical University (Sechenov University)Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)160920210610202118344922308202123082021Copyright ©; 2021, Pharmarus Print MediaCopyright ©; 2021, Фармарус Принт Медиа2021Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/1474

Atopic dermatitis is one of the most common diseases (20‒40% among skin diseases) that occur in both genders worldwide and in different age groups. The problem urgency is caused by an increase in morbidity, a chronic relapsing course that often leads to a decrease in the quality of life and disability, low efficiency of traditional treatment methods, and limited access to contemporary effective targeted therapy. The clinical guidelines, which aimed to optimize care for patients with atopic dermatitis, contain up-to-date information on epidemiology, etiological factors, mechanisms of development and pathogenesis, aspects of the clinical presentation and disease course, current diagnostic methods (including allergological examination methods), as well as approaches to treatment (including traditional methods and modern targeted therapy). The indications for allergen-specific immunotherapy are determined, and the aspects of its implementation are described. The procedure for the provision of medical care, prevention, and follow-up monitoring is outlined. Clinical practice guidelines for atopic dermatitis are intended for practitioners of all specialties, students, teachers of medical schools, residents, graduate students, and researchers.

Атопический дерматит ― одно из наиболее распространённых заболеваний (от 20 до 40% в структуре кожных заболеваний), встречающееся во всех странах у лиц обоего пола и в разных возрастных группах. Актуальность проблемы обусловлена ростом заболеваемости, хроническим рецидивирующим течением, нередко приводящим к снижению качества жизни и инвалидизации, низкой эффективностью традиционных методов лечения и ограничением доступности к современной эффективной таргетной терапии. Представленные клинические рекомендации, целью которых является оптимизация помощи больным атопическим дерматитом, содержат актуальную информацию об эпидемиологии, этиологических факторах, механизмах развития и патогенезе, особенностях клинической картины и течения заболевания, современных методах диагностики, включая аллергологические методы обследования, а также подходы к лечению, в том числе традиционные методы и современную таргетную терапию. Определены показания к аллергенспецифической иммунотерапии и описаны особенности её проведения. Изложен порядок оказания медицинской помощи, профилактики и диспансерного наблюдения. Клинические рекомендации по атопическому дерматиту предназначены для практикующих врачей всех специальностей, студентов, преподавателей медицинских вузов, ординаторов, аспирантов и научных работников.

atopic dermatitisepidemiologypathogenesisclinical coursetherapytopical therapysystemic therapyallergen-specific therapybiological therapyclinical guidelinesатопический дерматитэпидемиологияпатогенезклиническая картинадиагностикатерапиянаружная терапиясистемная терапияаллерген-специфическая иммунотерапиябиологическая терапияклинические рекомендацииPalmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446. doi: 10.1038/ng1767Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis // Nat Genet. 2006. Vol. 38, N 4. Р. 441–446. doi: 10.1038/ng1767McGirt LY, Beck LA. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):202–208. doi: 10.1016/j.jaci.2006.04.033McGirt L.Y., Beck L.A. Innate immune defects in atopic dermatitis // J Allergy Clin Immunol. 2006. Vol. 118, N 1. Р. 202–208. doi: 10.1016/j.jaci.2006.04.033Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137. doi: 10.4161/jkst.24137Bao L., Zhang H., Chan L.S. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis // JAKSTAT. 2013. Vol. 2, N 3. Р. e24137. doi: 10.4161/jkst.24137Gandhi NA, Pirozzi G, Graham N.M. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi: 10.1080/1744666X.2017.1298443Gandhi N.A., Pirozzi G., Graham N.M. Commonality of the IL-4/IL-13 pathway in atopic diseases // Expert Rev Clin Immunol. 2017. Vol. 13, N 5. Р. 425–437. doi: 10.1080/1744666X.2017.1298443Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–349. doi: 10.1016/j.jaci.2016.06.010Werfel T., Allam J.P., Biedermann T., et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis // J Allergy Clin Immunol. 2016. Vol. 138, N 2. Р. 336–349. doi: 10.1016/j.jaci.2016.06.010Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891Wollenberg A., Barbarot S., Bieber T., et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I // J Eur Acad Dermatol Venereol. 2018. Vol. 32, N 5. Р. 657–682. doi: 10.1111/jdv.14891Kubanov AA, Bogdanova EV. Organization and results of medical care in the profile of dermatovenerology in the Russian Federation. The results of 2018. Bulletin of Dermatology and Venereology. 2019;95(4):8–23. (In Russ). doi: 10.25208/0042-4609-2019-95-4-8-23Кубанов А.А., Богданова Е.В. Организация и результаты оказания медицинской помощи по профилю дерматовенерология в Российской Федерации. Итоги 2018 года // Вестник дерматологии и венерологии. 2019. Т. 95, № 4. C. 8–23. doi: 10.25208/0042-4609-2019-95-4-8-23Schneider L, Hanifin J, Boguniewicz M, et al. Study of the atopic march: development of atopic comorbidities. Pediatr Dermatol. 2016;33(4):388–398. doi: 10.1111/pde.12867Schneider L., Hanifin J., Boguniewicz M., et al. Study of the atopic march: development of atopic comorbidities // Pediatr Dermatol. 2016. Vol. 33, N 4. Р. 388–398. doi: 10.1111/pde.12867Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475–1482. doi: 10.1111/all.12049Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine // Allergy. 2012. Vol. 67, N 12. Р. 1475–1482. doi: 10.1111/all.12049Van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120(3):565–569. doi: 10.1016/j.jaci.2007.05.042Van der Hulst A.E., Klip H., Brand P.L. Risk of developing asthma in young children with atopic eczema: a systematic review // J Allergy Clin Immunol. 2007. Vol. 120, N 3. Р. 565–569. doi: 10.1016/j.jaci.2007.05.042Eckert L, Gupta S, Amand C, et al. The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol. 2018;78(1):54–61.e1. doi: 10.1016/j.jaad.2017.08.002Eckert L., Gupta S., Amand C., et al. The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey // J Am Acad Dermatol. 2018. Vol. 78, N 1. Р. 54–61.e1. doi: 10.1016/j.jaad.2017.08.002Illi S, von Mutius E, Lau S, et al. The pattern of atopic sensitization is associated with the development of asthma in childhood. J Allergy Clin Immunol. 2001;108(5):709–714. doi: 10.1067/mai.2001.118786Illi S., von Mutius E., Lau S., et al. The pattern of atopic sensitization is associated with the development of asthma in childhood // J Allergy Clin Immunol. 2001. Vol. 108, N 5. Р. 709–714. doi: 10.1067/mai.2001.118786Aw M, Penn J, Gauvreau GM, et al. Atopic march: collegium internationale allergologicum update 2020. Int Arch Allergy Immunol. 2020;181(1):1–10. doi: 10.1159/000502958Aw M., Penn J., Gauvreau G.M., et al. Atopic march: collegium internationale allergologicum update 2020 // Int Arch Allergy Immunol. 2020. Vol. 181, N 1. Р. 1–10. doi: 10.1159/000502958Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin N Am. 2010;30(3):269–280. doi: 10.1016/j.iac.2010.06.003Spergel J.M. Epidemiology of atopic dermatitis and atopic march in children // Immunol Allergy Clin N Am. 2010. Vol. 30, N 3. Р. 269–280. doi: 10.1016/j.iac.2010.06.003Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131–137. doi: 10.1016/j.anai.2017.10.037Hill D.A., Spergel J.M. The atopic march: Critical evidence and clinical relevance // Ann Allergy Asthma Immunol. 2018. Vol. 120, N 2. Р. 131–137. doi: 10.1016/j.anai.2017.10.037Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):209–213. doi: 10.1016/j.jaci.2006.04.043Williams H., Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis // J Allergy Clin Immunol. 2006. Vol. 118, N 1. Р. 209–213. doi: 10.1016/j.jaci.2006.04.043Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925–931. doi: 10.1016/j.jaci.2004.01.778Illi S., von Mutius E., Lau S., et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma // J Allergy Clin Immunol. 2004. Vol. 113, N 5. Р. 925–931. doi: 10.1016/j.jaci.2004.01.778Atopic dermatitis: recommendations for practitioners. The Russian conciliatory national document on atopic dermatitis. Ed. by P.M. Khaitov, A.A. Kubanov. Moscow: Pharmacus Print; 2002. 192 p. (In Russ).Атопический дерматит: рекомендации для практических врачей. Российский согласительный национальный документ по атопическому дерматиту / под ред. P.M. Хаитова, А.А. Кубановой. Москва: Фармакус Принт, 2002. 192 с.Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;60(92):44–47. doi: 10.2340/00015555924447Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis // Acta Derm Venereol. 1980. Vol. 60, N 92. Р. 44–47. doi: 10.2340/00015555924447Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351. doi: 10.1016/j.jaad.2013.10.010Eichenfield L.F., Tom W.L., Chamlin S.L., et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis // J Am Acad Dermatol. 2014. Vol. 70, N 2. Р. 338–351. doi: 10.1016/j.jaad.2013.10.010Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010;63(6):949–972. doi: 10.1016/j.jaad.2010.02.062Ryan C., Amor K.T., Menter A. The use of cyclosporine in dermatology: part II // J Am Acad Dermatol. 2010. Vol. 63, N 6. Р. 949–972. doi: 10.1016/j.jaad.2010.02.062Arbes SJ, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005;116(2):377–383. doi: 10.1016/j.jaci.2005.05.017Arbes S.J., Gergen P.J., Elliott L., Zeldin D.C. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey // J Allergy Clin Immunol. 2005. Vol. 116, N 2. Р. 377–383. doi: 10.1016/j.jaci.2005.05.017Clinical dermatovenerology. Vol. II. Ed. by Yu.K. Skripkin, Yu.S. Butov. Moscow: GEOTAR-Media; 2009. 928 p.Клиническая дерматовенерология: в 2 т. Т. II / под ред. Ю.К. Скрипкина, Ю.С. Бутова. Москва: ГЭОТАР-Медиа, 2009. 928 с.Futamura M, Leshem YA, Thomas KS, et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. J Am Acad Dermatol. 2016;74(2):288–294. doi: 10.1016/j.jaad.2015.09.062Futamura M., Leshem Y.A., Thomas K.S., et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards // J Am Acad Dermatol. 2016. Vol. 74, N 2. Р. 288–294. doi: 10.1016/j.jaad.2015.09.062Oranje AP, Stalder JF, Taieb A, et al. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child. Pediatr Allergy Immunol. 1997;8(1):28–34. doi: 10.1111/j.1399-3038.1997.tb00139.xOranje A.P., Stalder J.F., Taieb A., et al. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child // Pediatr Allergy Immunol. 1997. Vol. 8, N 1. Р. 28–34. doi: 10.1111/j.1399-3038.1997.tb00139.xSchram ME, Spuls PI, Leeflang MM, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106. doi: 10.1111/j.1398-9995.2011.02719.xSchram M.E., Spuls P.I., Leeflang M.M., et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference // Allergy. 2012. Vol. 67, N 1. Р. 99–106. doi: 10.1111/j.1398-9995.2011.02719.xGiam Y.C., Hebert A.A., Dizon M.V. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy. 2016;6(2):120–128. doi: 10.5415/apallergy.2016.6.2.120Giam Y.C., Hebert A.A., Dizon M.V. A review on the role of moisturizers for atopic dermatitis // Asia Pac Allergy. 2016. Vol. 6, N 2. Р. 120–128. doi: 10.5415/apallergy.2016.6.2.120Breternitz M, Kowatzki D, Langenauer M, et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008;21(1):39–45. doi: 10.1159/000111134Breternitz M., Kowatzki D., Langenauer M., et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation // Skin Pharmacol Physiol. 2008. Vol. 21, N 1. Р. 39–45. doi: 10.1159/000111134Verallo-Rowell VM, Dillague KM, Syah-Tjundawan BS. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis. 2008;19(6):308–315.Verallo-Rowell V.M., Dillague K.M., Syah-Tjundawan B.S. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis // Dermatitis. 2008. Vol. 19, N 6. Р. 308–315.Simpson E, Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. J Drugs Dermatol. 2011;10(7):744–749.Simpson E., Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults // J Drugs Dermatol. 2011. Vol. 10, N 7. Р. 744–749.Lindh JD, Bradley M. Clinical effectiveness of moisturizers in atopic dermatitis and related disorders: a systematic review. Am J Clin Dermatol. 2015;16(5):341–359. doi: 10.1007/s40257-015-0146-4Lindh J.D., Bradley M. Clinical effectiveness of moisturizers in atopic dermatitis and related disorders: a systematic review // Am J Clin Dermatol. 2015. Vol. 16, N 5. Р. 341–359. doi: 10.1007/s40257-015-0146-4Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol. 2011;10(5):531–537.Miller D.W., Koch S.B., Yentzer B.A., et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial // J Drugs Dermatol. 2011. Vol. 10, N 5. Р. 531–537.Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214(1):61–67. doi: 10.1159/000096915Grimalt R., Mengeaud V., Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study // Dermatology. 2007. Vol. 214, N 1. Р. 61–67. doi: 10.1159/000096915Msika P, De Belilovsky C, Piccardi N, et al. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol. 2008;25(6):606–612. doi: 10.1111/j.1525-1470.2008.00783.xMsika P., De Belilovsky C., Piccardi N., et al. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement // Pediatr Dermatol. 2008. Vol. 25, N 6. Р. 606–612. doi: 10.1111/j.1525-1470.2008.00783.xLucky AW, Leach AD, Laskarzewski P, Wenck H. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997;14(4):321–324. doi: 10.1111/j.1525-1470.1997.tb00968.xLucky A.W., Leach A.D., Laskarzewski P., Wenck H. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children // Pediatr Dermatol. 1997. Vol. 14, N 4. Р. 321–324. doi: 10.1111/j.1525-1470.1997.tb00968.xEberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008;22(1):73–82. doi: 10.1111/j.1468-3083.2007.02351.xEberlein B., Eicke C., Reinhardt H.W., Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study) // J Eur Acad Dermatol Venereol. 2008. Vol. 22, N 1. Р. 73–82. doi: 10.1111/j.1468-3083.2007.02351.xSugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol. 2009;8(12):1106–1111.Sugarman J.L., Parish L.C. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis // J Drugs Dermatol. 2009. Vol. 8, N 12. Р. 1106–1111.Leung TN, Chow CM, Chow MP, et al. Clinical guidelines on management of atopic dermatitis in children. Hong Kong J Paediatr (new series). 2013;18(2):96–104.Leung T.N., Chow C.M., Chow M.P., et al. Clinical guidelines on management of atopic dermatitis in children // Hong Kong J Paediatr (new series). 2013. Vol. 18, N 2. Р. 96–104.Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV Eczema Task Force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010;24(3):317–328. doi: 10.1111/j.1468-3083.2009.03415.xDarsow U., Wollenberg A., Simon D., et al. ETFAD/EADV Eczema Task Force 2009 position paper on diagnosis and treatment of atopic dermatitis // J Eur Acad Dermatol Venereol. 2010. Vol. 24, N 3. Р. 317–328. doi: 10.1111/j.1468-3083.2009.03415.xChiang C, Eichenfield LF. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol. 2009;26(3):273–278. doi: 10.1111/j.1525-1470.2009.00911.xChiang C., Eichenfield L.F. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis // Pediatr Dermatol. 2009. Vol. 26, N 3. Р. 273–278. doi: 10.1111/j.1525-1470.2009.00911.xGuidance on Prescribing. In: British National Formulary No.60. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2010.Dabade TS, Davis DM, Wetter DA, et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol. 2012;67(1):100–106. doi: 10.1016/j.jaad.2011.06.025Dabade T.S., Davis D.M., Wetter D.A., et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic // J Am Acad Dermatol. 2012. Vol. 67, N 1. Р. 100–106. doi: 10.1016/j.jaad.2011.06.025Devillers AC, Oranje AP. Efficacy and safety of ‘wet-wrap’ dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol. 2006;154(4):579–585. doi: 10.1111/j.1365-2133.2006.07157.xDevillers A.C., Oranje A.P. Efficacy and safety of ‘wet-wrap’ dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature // Br J Dermatol. 2006. Vol. 154, N 4. Р. 579–585. doi: 10.1111/j.1365-2133.2006.07157.xDevillers AC, de Waard-van der Spek FB, Mulder PG, Oranje AP. Treatment of refractory atopic dermatitis using ‘wet-wrap’ dressings and diluted corticosteroids: results of standardized treatment in both children and adults. Dermatology. 2002;204(1):50–55. doi: 10.1159/000051810Devillers A.C., de Waard-van der Spek F.B., Mulder P.G., Oranje A.P. Treatment of refractory atopic dermatitis using ‘wet-wrap’ dressings and diluted corticosteroids: results of standardized treatment in both children and adults // Dermatology. 2002. Vol. 204, N 1. Р. 50–55. doi: 10.1159/000051810Goodyear HM, Spowart K, Harper JI. ‘Wet-wrap’ dressings for the treatment of atopic eczema in children. Br J Dermatol. 1991;125(6):604. doi: 10.1111/j.1365-2133.1991.tb14807.xGoodyear H.M., Spowart K., Harper J.I. ‘Wet-wrap’ dressings for the treatment of atopic eczema in children // Br J Dermatol. 1991. Vol. 125, N 6. Р. 604. doi: 10.1111/j.1365-2133.1991.tb14807.xBrenninkmeijer EE, Spuls PI, Lindeboom R, et al. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. Br J Dermatol. 2010;163(4):823–831. doi: 10.1111/j.1365-2133.2010.09858.xBrenninkmeijer E.E., Spuls P.I., Lindeboom R., et al. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot // Br J Dermatol. 2010. Vol. 163, N 4. Р. 823–831. doi: 10.1111/j.1365-2133.2010.09858.xPels R, Sterry W, Lademann J. Clobetasol propionate ― where, when, why? Drugs Today (Barc). 2008;44(7):547–557. doi: 10.1358/dot.2008.44.7.1122221Pels R., Sterry W., Lademann J. Clobetasol propionate ― where, when, why? // Drugs Today (Barc). 2008. Vol. 44, N 7. Р. 547–557. doi: 10.1358/dot.2008.44.7.1122221Breneman D, Fleischer AB, Kaplan D, et al. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. J Drugs Dermatol. 2005;4(3):330–336.Breneman D., Fleischer A.B., Kaplan D., et al. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream // J Drugs Dermatol. 2005. Vol. 4, N 3. Р. 330–336.Feldman SR. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Curr Ther Res Clin Exp. 2005;66(3):154–171. doi: 10.1016/j.curtheres.2005.06.010Feldman S.R. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses // Curr Ther Res Clin Exp. 2005. Vol. 66, N 3. Р. 154–171. doi: 10.1016/j.curtheres.2005.06.010Datz B, Yawalkar S. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991;25(6 Pt 2):1157–1160. doi: 10.1016/0190-9622(91)70316-tDatz B., Yawalkar S. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus // J Am Acad Dermatol. 1991. Vol. 25, N 6, Pt 2. Р. 1157–1160. doi: 10.1016/0190-9622(91)70316-tViglioglia P, Jones ML, Peets EA. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses. J Int Med Res. 1990;18(6):460–467. doi: 10.1177/030006059001800603Viglioglia P., Jones M.L., Peets E.A. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses // J Int Med Res. 1990. Vol. 18, N 6. Р. 460–467. doi: 10.1177/030006059001800603Vanderploeg DE. Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study. South Med J. 1976;69(7):862–863. doi: 10.1097/00007611-197607000-00017Vanderploeg D.E. Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study // South Med J. 1976. Vol. 69, N 7. Р. 862–863. doi: 10.1097/00007611-197607000-00017Queille C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol. 1984;1(3):246–253.Queille C., Pommarede R., Saurat J.H. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood // Pediatr Dermatol. 1984. Vol. 1, N 3. Р. 246–253.Cabrera ME. Treatment of severe or resistant corticosteroid-responsive dermatoses with Diprolene cream. J Int Med Res. 1984;12(3):163–169. doi: 10.1177/030006058401200305Cabrera M.E. Treatment of severe or resistant corticosteroid-responsive dermatoses with Diprolene cream // J Int Med Res. 1984. Vol. 12, N 3. Р. 163–169. doi: 10.1177/030006058401200305Lodolo JC. Diprolene cream in the treatment of severe or resistant corticosteroid-responsive dermatoses. J Int Med Res. 1984;12(2):114–120. doi: 10.1177/030006058401200209Lodolo J.C. Diprolene cream in the treatment of severe or resistant corticosteroid-responsive dermatoses // J Int Med Res. 1984. Vol. 12, N 2. Р. 114–120. doi: 10.1177/030006058401200209Peterkin GA, Morley WN, Chalmers D. Triamcinolone and fluocinolone acetonide ointments in atopic eczema. Br Med J. 1962;1(5289):1392. doi: 10.1136/bmj.1.5289.1392Peterkin G.A., Morley W.N., Chalmers D. Triamcinolone and fluocinolone acetonide ointments in atopic eczema // Br Med J. 1962. Vol. 1, N 5289. Р. 1392. doi: 10.1136/bmj.1.5289.1392Hanifin JM. Atopic dermatitis. Special clinical complications. Postgrad Med. 1983;74(3):188–199. doi: 10.1080/00325481.1983.11698425Hanifin J.M. Atopic dermatitis. Special clinical complications // Postgrad Med. 1983. Vol. 74, N 3. Р. 188–199. doi: 10.1080/00325481.1983.11698425Cadmus SD, Sebastian KR, Warren D, et al. Efficacy and patient opinion of wet‐wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: A randomized split‐body control study. Pediatr Dermatol. 2019;36(4):437–441.Cadmus S.D., Sebastian K.R., Warren D. et al. Efficacy and patient opinion of wet‐wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: a randomized split‐body control study // PediatrDermatol. 2019. Vol. 36, N 4. Р. 437–441.Wolkerstorfer A, Strobos MA, Glazenburg EJ, et al. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol. 1998;39(2 Pt 1):226–231. doi: 10.1016/s0190-9622(98)70080-5Wolkerstorfer A., Strobos M.A., Glazenburg E.J., et al. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis // J Am Acad Dermatol. 1998. Vol. 39, N 2, Pt 1. Р. 226–231. doi: 10.1016/s0190-9622(98)70080-5Bleehen SS, Chu AC, Hamann I, et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol. 1995;133(4):592–597. doi: 10.1111/j.1365-2133.1995.tb02711.xBleehen S.S., Chu A.C., Hamann I., et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment // Br J Dermatol. 1995. Vol. 133, N 4. Р. 592–597. doi: 10.1111/j.1365-2133.1995.tb02711.xBelousova TA, Goryachkina MV. Experience of using fluticasone propionate (Kutivate) in the treatment of psoriasis, eczema and atopic dermatitis. Effective Pharmacotherapy. 2010;(9):24–29. (In Russ).Белоусова Т.А., Горячкина М.В. Опыт применения флутиказона пропионата (Кутивейт) в терапии псориаза, экземы и атопического дерматита // Эффективная фармакотерапия. 2010. № 9. P. 24–29.Prakash A, Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs. 1998;55(1):145–163. doi: 10.2165/00003495-199855010-00009Prakash A., Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders // Drugs. 1998. Vol. 55, N 1. Р. 145–163. doi: 10.2165/00003495-199855010-00009Vernon HJ, Lane AT, Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol. 1991;24(4):603–607. doi: 10.1016/0190-9622(91)70092-gVernon H.J., Lane A.T., Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis // J Am Acad Dermatol. 1991. Vol. 24, N 4. Р. 603–607. doi: 10.1016/0190-9622(91)70092-gLebwohl M. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. Int J Dermatol. 1999;38(8):604–606. doi: 10.1046/j.1365-4362.1999.00759.xLebwohl M. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group // Int J Dermatol. 1999. Vol. 38, N 8. Р. 604–606. doi: 10.1046/j.1365-4362.1999.00759.xTomilova AYu, Torshkhoeva RM, Gevorkyan AK, Voznesenskaya NI. Efficacy and safety of mometasone furoate in atopic dermatitis in children. Pediatric Pharmacology. 2009;6(4):123–127. (In Russ).Томилова А.Ю., Торшхоева Р.М., Геворкян А.К., Вознесенская Н.И. Эффективность и безопасность применения мометазона фуроата при атопическом дерматите у детей // Педиатрическая фармакология. 2009. Т. 6, №4. С. 123–127.Shaipov TS, Mazitova LP. The use of mometasone furoate in the treatment of atopic dermatitis in children. Pediatric Pharmacology. 2007;4(5):41–44. (In Russ).Шаипов Т.С., Мазитова Л.П. Применение мометазона фуроата при лечении атопического дерматита у детей // Педиатрическая фармакология. 2007. Т. 4, № 5. С. 41–44.Nenasheva NM. Features of atopic dermatitis in adult patients Effective pharmacotherapy. Dermatovenerology and Dermatocosmetology. 2012;(3):6–15. (In Russ).Ненашева Н.М. Особенности атопического дерматита у взрослых пациентов Эффективная фармакотерапия // Дерматовенерология и дерматокосметология. 2012. № 3. С. 6–15.Lane AT. Efficacy and safety of topical steroids in paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 1997;8:S24–S27.Lane A.T. Efficacy and safety of topical steroids in paediatric atopic dermatitis // J Eur Acad Dermatol Venereol. 1997. Vol. 8. Р. S24–S27.Faergemann J, Christensen O, Sjövall P, et al. An open study of efficacy and safety of long‐term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2000;14(5):393–396.Faergemann J., Christensen O., Sjövall P. et al. An open study of efficacy and safety of long‐term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis // J Eur Acad Dermatol Venereol. 2000. Vol. 14, N 5. Р. 393–396.Haneke E. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid. J Dermatol Treatm. 2009;3(Suppl. 2):13–15. doi: 10.3109/09546639209092767Haneke E. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid // J Dermatol Treatm. 2009. Vol. 3, Suppl. 2. Р. 13–15. doi: 10.3109/09546639209092767Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25(3):251–258. doi: 10.1111/j.1468-3083.2010.03789.xLuger T.A. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate // J Eur Acad Dermatol Venereol. 2011. Vol. 25, N 3. Р. 251–258. doi: 10.1111/j.1468-3083.2010.03789.xBieber T, Vick K, Fölster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62(2):184–189. doi: 10.1111/j.1398-9995.2006.01269.xBieber T., Vick K., Fölster-Holst R., et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis // Allergy. 2007. Vol. 62, N 2. Р. 184–189. doi: 10.1111/j.1398-9995.2006.01269.xKondratieva YuS, Karkhova VV. Experience of using 0.1% methylprednisolone aceponate in the complex therapy of steroid-sensitive dermatoses. Bulletin of Dermatology and Venereology. 2016;(1):93–98. (In Russ).Кондратьева Ю.С., Кархова В.В. Опыт применения 0,1% метилпреднизолона ацепоната в комплексной терапии стероидчувствительных дерматозов // Вестник дерматологии и венерологии. 2016. № 1. С. 93–98.Chikin VV. Methylprednisolone aceponate and dexpanthenol in topical therapy of patients with AtD. Bulletin of Dermatology and Venereology. 2014;90(5):112–116. (In Russ). doi: 10.25208/0042-4609-2014-90-5-112-116Чикин В.В. Метилпреднизолона ацепонат и декспантенол в топической терапии больных АтД // Вестник дерматологии и венерологии 2014. T. 90, № 5. С. 112–116. doi: 10.25208/0042-4609-2014-90-5-112-116Lassus A. Alclometasone dipropionate cream 0.05% versus clobetasone butyrate cream 0.05%. A controlled clinical comparison in the treatment of atopic dermatitis in children. Int J Dermatol. 1984;23(8):565–566. doi: 10.1111/j.1365-4362.1984.tb04214.xLassus A. Alclometasone dipropionate cream 0.05% versus clobetasone butyrate cream 0.05%. A controlled clinical comparison in the treatment of atopic dermatitis in children // Int J Dermatol. 1984. Vol. 23, N 8. Р. 565–566. doi: 10.1111/j.1365-4362.1984.tb04214.xPanja SK, Gangopadhaya AK, Sharma SD. A randomised, double-blind comparison of alclometasone dipropionate 0.05% cream in atopic dermatitis and other dermatoses. Indian J Dermatol. 1988;33(1):1–4.Panja S.K., Gangopadhaya A.K., Sharma S.D. A randomised, double-blind comparison of alclometasone dipropionate 0.05% cream in atopic dermatitis and other dermatoses // Indian J Dermatol. 1988. Vol. 33, N 1. Р. 1–4.Makarova IV, Gaiduk IM, Zhiglinskaya OV, et al. The use of 0.05% cream of alclomethasone dipropionate in the treatment of atopic dermatitis in young children. Questions of Modern Pediatrics. 2004;3(4):84–87. (In Russ).Макарова И.В., Гайдук И.М., Жиглинская О.В., и др. Применение 0,05% крема алклометазона дипропионата в терапии атопического дерматита у детей раннего возраста // Вопросы современной педиатрии. 2004. Т. 3, № 4. С. 84–87.Korotky NG, Tikhomirov AA, Gamayunov BN. Evaluation of the clinical efficacy of the modern steroid alclomethasone dipropionate (Afloderm) in the external therapy of atopic dermatitis in children. Clinical Dermatology and Venereology. 2007;(6):24–31. (In Russ).Короткий Н.Г., Тихомиров А.А., Гамаюнов Б.Н. Оценка клинической эффективности современного стероида алклометазонадипропионата (Афлодерма) в наружной терапии атопического дерматита у детей // Клиническая дерматология и венерология. 2007. № 6. С. 24–31.Toropova NP, Cherkasova LA, Platonova IN, et al. Experience of using the drug “Afloderm” (alclomethasone dipropionate) in pediatric dermatological practice. Russian Journal of Skin and Venereal Diseases. 2003;(3):39–40. (In Russ).Торопова Н.П., Черкасова Л.А., Платонова И.Н., и др. Опыт применения препарата «Афлодерм» (алклометазонадипропионат) в детской дерматологической практике // Российский журнал кожных и венерических болезней. 2003. № 3. С. 39–40.Veien NK, Hattel T, Justesen O, et al. Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis. J Int Med Res. 1984;12(5):310–313. doi: 10.1177/030006058401200509Veien N.K., Hattel T., Justesen O., et al. Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis // J Int Med Res. 1984. Vol. 12, N 5. Р. 310–313. doi: 10.1177/030006058401200509Rajka G, Verjans HL. Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering from atopic dermatitis. J Int Med Res. 1986;14(2):85–90. doi: 10.1177/030006058601400206Rajka G., Verjans H.L. Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering from atopic dermatitis // J Int Med Res. 1986. Vol. 14, N 2. Р. 85–90. doi: 10.1177/030006058601400206Abramovits A, Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. SKINmed. 2010;8(2):72–79.Abramovits A., Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis // SKINmed. 2010. Vol. 8, N 2. Р. 72–79.Koopmans B, Lasthein Andersen B, Mork NJ, et al. Multicentre randomized double-blind study of locoid lipocream fatty cream twice daily versus locoid lipocream once daily and locobase once daily. J Dermatol Treat. 1995;6(2):103–106. doi: 10.3109/09546639509097161Koopmans B., Lasthein Andersen B., Mork N.J., et al. Multicentre randomized double-blind study of locoid lipocream fatty cream twice daily versus locoid lipocream once daily and locobase once daily // J Dermatol Treat. 1995. Vol. 6, N 2. Р. 103–106. doi: 10.3109/09546639509097161Saki N, Jowkar F, Alyaseen S, et al. Comparison of sertaconazole 2% cream versus hydrocortisone 1% ointment in the treatment of atopic dermatitis. J Dermatolog Treat. 2013;24(6):447–449. doi: 10.3109/09546634.2013.782384Saki N., Jowkar F., Alyaseen S., et al. Comparison of sertaconazole 2% cream versus hydrocortisone 1% ointment in the treatment of atopic dermatitis // J Dermatolog Treat. 2013. Vol. 24, N 6. Р. 447–449. doi: 10.3109/09546634.2013.782384Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002;109(3):547–555. doi: 10.1067/mai.2002.121832Reitamo S., Rustin M., Ruzicka T., et al. Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis // J Allergy Clin Immunol. 2002. Vol. 109, N 3. Р. 547–555. doi: 10.1067/mai.2002.121832Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008;7(3):266–271.Matheson R., Kempers S., Breneman D., et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects // J Drugs Dermatol. 2008. Vol. 7, N 3. Р. 266–271.Sears HW, Bailer JW, Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther. 1997;19(4):710–719.Sears H.W., Bailer J.W., Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis // Clin Ther. 1997. Vol. 19, N 4. Р. 710–719.Ignatiev DV, Kochergin NG. Local corticosteroids in the practice of a dermatologist. Features of hydrocortisone butyrate (locoid). Dermatology. Appendix Journal Consilium Medicum. 2007;(1):50–54. (In Russ).Игнатьев Д.В., Кочергин Н.Г. Местные кортикостероиды в практике врача-дерматолога. Особенности гидрокортизона бутирата (локоида) // Дерматология. Приложение к журналу Consilium Medicum. 2007. № 1. C. 50–54.Udompataikul M, Limpa-o-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11(3):366–374.Udompataikul M., Limpa-o-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study // J Drugs Dermatol. 2012. Vol. 11, N 3. Р. 366–374.Udompataikul M, Srisatwaja W. Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study. J Eur Acad Dermatol Venereol. 2011;25(6):660–665.Udompataikul M., Srisatwaja W. Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study // J Eur Acad Dermatol Venereol. 2011. Vol. 25, N 6. Р. 660–665.Sergeev YuV, Ivanov OL, Novikov DK, et al. Atopic dermatitis: modern diagnosis and treatment. Immunopathology, Allergology, Infectology. 2001;(4):39–63. (In Russ).Сергеев Ю.В., Иванов О.Л., Новиков Д.К., и др. Атопический дерматит: современная диагностика и лечение // Иммунопатология, аллергология, инфектология. 2001. № 4. C. 39–63.Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005;330(7490):516.Ashcroft D.M., Dimmock P., Garside R., et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials // BMJ. 2005. Vol. 330, N 7490. Р. 516.Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997;337(12):816–821. doi: 10.1056/NEJM199709183371203Ruzicka T., Bieber T., Schöpf E., et al. A short-term trial of tacrolimus ointment for atopic dermatitis // N Engl J Med. 1997. Vol. 337, N 12. Р. 816–821. doi: 10.1056/NEJM199709183371203Reitamo S, Wollenberg A, Schöpf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol. 2000;136(8):999–1006. doi: 10.1001/archderm.136.8.999Reitamo S., Wollenberg A., Schöpf E., et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis // Arch Dermatol. 2000. Vol. 136, N 8. Р. 999–1006. doi: 10.1001/archderm.136.8.999Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010;21(3):144–156. doi: 10.3109/09546630903401470Chen S.L., Yan J., Wang F.S. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials // J Dermatolog Treat. 2010. Vol. 21, N 3. Р. 144–156. doi: 10.3109/09546630903401470Bornhövd EC, Burgdorf WH, Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opin Investig Drugs. 2002;3(5):708–712.Bornhövd E.C., Burgdorf W.H., Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases // Curr Opin Investig Drugs. 2002. Vol. 3, N 5. Р. 708–712.Lubbe J. Klinische Erfahrungen mit topischen Calcineurininhibitoren in der Praxis. Hautarzt. 2003;54(5):432–439.Lubbe J. Klinische Erfahrungen mit topischen Calcineurininhibitoren in der Praxis // Hautarzt. 2003. Vol. 54, N 5. Р. 432–439.Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152(6):1282–1289. doi: 10.1111/j.1365-2133.2005.06592.xReitamo S., Ortonne J.P., Sand C., et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis // Br J Dermatol. 2005. Vol. 152, N 6. Р. 1282–1289. doi: 10.1111/j.1365-2133.2005.06592.xPatel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol. 2003;139(9):1184–1186. doi: 10.1001/archderm.139.9.1184Patel R.R., Vander Straten M.R., Korman N.J. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis // Arch Dermatol. 2003. Vol. 139, N 9. Р. 1184–1186. doi: 10.1001/archderm.139.9.1184Wollenberg A, Sidhu MK, Odeyemi I, et al. Economic evaluation of secondary prophylactic treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2008;159(6):1322–1330. doi: 10.1111/j.1365-2133.2008.08807.xWollenberg A., Sidhu M.K., Odeyemi I., et al. Economic evaluation of secondary prophylactic treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis // Br J Dermatol. 2008. Vol. 159, N 6. Р. 1322–1330. doi: 10.1111/j.1365-2133.2008.08807.xHealy E, Bentley A, Fidler C, Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twicedaily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol. 2011;164(2):387–395. doi: 10.1111/j.1365-2133.2010.10141.xHealy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twicedaily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective // Br J Dermatol. 2011. Vol. 164, N 2. Р. 387–395. doi: 10.1111/j.1365-2133.2010.10141.xReitamo S, Mandelin J, Rubins A, et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol. 2009;48(4):348–355. doi: 10.1111/j.1365-4632.2009.03853.xReitamo S., Mandelin J., Rubins A., et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis // Int J Dermatol. 2009. Vol. 48, N 4. Р. 348–355. doi: 10.1111/j.1365-4632.2009.03853.xReitamo S, Rustin M, Harper J, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008;159(4):942–951. doi: 10.1111/j.1365-2133.2008.08747.x RuzickaReitamo S., Rustin M., Harper J., et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients // Br J Dermatol. 2008. Vol. 159, N 4. Р. 942–951. doi: 10.1111/j.1365-2133.2008.08747.x RuzickaMandelin JM, Remitz A, Virtanen HM, et al. A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years. J Dermatolog Treat. 2010;21(3):167–170. doi: 10.3109/09546630903493329Mandelin J.M., Remitz A., Virtanen H.M., et al. A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years // J Dermatolog Treat. 2010. Vol. 21, N 3. Р. 167–170. doi: 10.3109/09546630903493329Mandelin J, Remitz A, Virtanen HM, et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol. 2010;90(2):170–174. doi: 10.2340/00015555-0803Mandelin J., Remitz A., Virtanen H.M., et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial // Acta Derm Venereol. 2010. Vol. 90, N 2. Р. 170–174. doi: 10.2340/00015555-0803Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998;102(4 Pt 1):637–644. doi: 10.1016/s0091-6749(98)70281-7Boguniewicz M., Fiedler V.C., Raimer S., et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group // J Allergy Clin Immunol. 1998. Vol. 102, N 4, Pt 1. Р. 637–644. doi: 10.1016/s0091-6749(98)70281-7Elisyutina OG, Fedenko ES, Shtyrbul OV, Niyazov DD. The use of tacrolimus in patients with moderate and severe atopic dermatitis. The first clinical experience in Russia. Russian Journal of Allergy. 2011;(6):68–76. (In Russ).Елисютина О.Г., Феденко Е.С., Штырбул О.В., Ниязов Д.Д. Применение такролимуса у больных атопическим дерматитом среднетяжелого и тяжелого течения. Первый клинический опыт в России // Российский аллергологический журнал. 2011. № 6. С. 68–76.Proshutinskaya DV, Butareva MM, Inoyatova LA. New possibilities of therapy of atopic dermatitis in children and adults. Bulletin of Dermatology and Venereology. 2013;(3):78–82. (In Russ).Прошутинская Д.В., Бутарева М.М., Иноятова Л.А. Новые возможности терапии атопического дерматита у детей и взрослых // Вестник дерматологии и венерологии. 2013. № 3. С. 78–82.Samtsov AV, Sukharev AV, Patrushev AV, Bondar OI. Clinical efficacy, safety and tolerability of 0.1% tacrolimus ointment in the treatment of moderate and severe atopic dermatitis. Bulletin of Dermatology and Venereology. 2012;(2):71–77. (In Russ).Самцов А.В., Сухарев А.В., Патрушев А.В., Бондарь О.И. Клиническая эффективность, безопасность и переносимость 0,1% мази такролимус при лечении атопического дерматита средней и тяжелой степени тяжести // Вестник дерматологии и венерологии. 2012. № 2. С. 71–77.Samtsov AV, Sukharev AV, Patrushev AV. Treatment of atopic dermatitis: advantages of tacrolimus over topical corticosteroids. Effective Pharmacotherapy. 2014;(19):4–10. (In Russ).Самцов А.В., Сухарев А.В., Патрушев А.В. Лечение атопического дерматита: преимущества такролимуса перед топическими кортикостероидами // Эффективная фармакотерапия. 2014. № 19. С. 4–10.Van Leent EJ, Graber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998;134(7):805–809. doi: 10.1001/archderm.134.7.805Van Leent E.J., Graber M., Thurston M., et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis // Arch Dermatol. 1998. Vol. 134, N 7. Р. 805–809. doi: 10.1001/archderm.134.7.805Meurer M, Fölster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205(3):271–277. doi: 10.1159/000065863Meurer M., Fölster-Holst R., Wozel G., et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study // Dermatology. 2002. Vol. 205, N 3. Р. 271–277. doi: 10.1159/000065863Wahn U, Bos J, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2. doi: 10.1542/peds.110.1.e2Wahn U., Bos J., Goodfield M., et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children // Pediatrics. 2002. Vol. 110, N 1, Pt 1. Р. e2. doi: 10.1542/peds.110.1.e2Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;142(2):155–162. doi: 10.1067/mpd.2003.65Ho V.C., Gupta A., Kaufmann R., et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants // J Pediatr. 2003. Vol. 142, N 2. Р. 155–162. doi: 10.1067/mpd.2003.65Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46(4):495–504. doi: 10.1067/mjd.2002.122187Eichenfield L.F., Lucky A.W., Boguniewicz M., et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents // J Am Acad Dermatol. 2002. Vol. 46, N 4. Р. 495–504. doi: 10.1067/mjd.2002.122187Langley RG, Eichenfield LF, Lucky AW, et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children withatopic dermatitis. Pediatr Dermatol. 2008;25(3):301–307. doi: 10.1111/j.1525-1470.2008.00671.xLangley R.G., Eichenfield L.F., Lucky A.W., et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children withatopic dermatitis // Pediatr Dermatol. 2008. Vol. 25, N 3. Р. 301–307. doi: 10.1111/j.1525-1470.2008.00671.xLuger T, van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001;144(4):788–794. doi: 10.1046/j.1365-2133.2001.04134.xLuger T., van Leent E.J., Graeber M., et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis // Br J Dermatol. 2001. Vol. 144, N 4. Р. 788–794. doi: 10.1046/j.1365-2133.2001.04134.xEichenfield LF, Thaci D, de Prost Y, et al. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. Dermatology. 2007;11(Suppl 1):3–17. doi: 10.1159/000102116Eichenfield L.F., Thaci D., de Prost Y., et al. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients // Dermatology. 2007. Vol. 11, Suppl 1. Р. 3–17. doi: 10.1159/000102116Reda AM, Elgendi A, Ebraheem AI, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatolog Treat. 2019;30(4):366–373. doi: 10.1080/09546634.2018.1524823Reda A.M., Elgendi A., Ebraheem A.I., et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas // J Dermatolog Treat. 2019. Vol. 30, N 4. Р. 366–373. doi: 10.1080/09546634.2018.1524823Kubanov AA, Petrovsky FI. Activated zinc pyrithione (Skin cap). Mechanisms of action. Clinical application. Bulletin of Dermatology and Venereology. 2009;(5):35–42. (In Russ).Кубанов А.А., Петровский Ф.И. Активированный пиритион цинка (Скин-кап). Механизмы действия. Клиническое применение // Вестник дерматологии и венерологии. 2009. № 5. С. 35–42.Fassakhov RS, Pampura AN, Korostovtsev DS, et al. Skin-Cap in the treatment of atopic dermatitis in children (according to the results of the Russian multicenter study KADET). Russian Journal of Allergy. 2007;(2):75–81. (In Russ).Фассахов Р.С., Пампура А.Н., Коростовцев Д.С., и др. Скин-Кап в терапии атопического дерматита у детей (по результатам российского многоцентрового исследования КАДЕТ) // Российский аллергологический журнал. 2007. № 2. С. 75–81.Fassakhov RS, Pampura AN, Korostovtsev DS, et al. Efficacy and safety of activated zinc pyrithione (skin cap) in the treatment of atopic dermatitis in children (results of a Russian multicenter study). Bulletin of Pediatric Pharmacology and Nutriciology. 2006;3(6):28–31. (In Russ).Фассахов Р.С., Пампура А.Н., Коростовцев Д.С., и др. Эффективность и безопасность активированного цинк пиритиона (скин-кап) в лечении атопического дерматита у детей (результаты российского многоцентрового исследования) // Вестник педиатрической фармакологии и нутрициологии. 2006. Т. 3, № 6. С. 28–31.Neurodermatoses. In: Skin and venereal diseases: A guide for doctors. In two volumes. 2nd ed., reprint. and additional vol. 2. Ed. by Yu.K. Skripkin, V.N. Mordovtsev. Moscow: Meditsina; 1999. Р. 9–49. (In Russ).Нейродерматозы. В кн.: Кожные и венерические болезни: Руководство для врачей. В двух томах. 2-е изд., перераб. и доп. Т. 2 / под ред. Ю.К. Скрипкина, В.Н. Мордовцева. Москва: Медицина, 1999. С. 9–49.Yoshida H, Niimura M, Ueda H, et al. Clinical evaluation of ketotifen syrup on atopic dermatitis: a comparative multicenter double-blind study of ketotifen and clemastine. Ann Allergy. 1989;62(6):507–512.Yoshida H., Niimura M., Ueda H., et al. Clinical evaluation of ketotifen syrup on atopic dermatitis: a comparative multicenter double-blind study of ketotifen and clemastine // Ann Allergy. 1989. Vol. 62, N 6. Р. 507–512.Grigorieva I, Sergeev A, Manina I, Kudryavtseva E. Immunopathology and biochemical bases of atopic states. Doctor. 2012;(4):86–91. (In Russ).Григорьева И., Сергеев А., Манина И., Кудрявцева Е. Иммунопатология и биохимические основы атопических состояний // Врач. 2012. № 4. С. 86–91.Morozova SV, Luss LV. Chloropyramine: modern aspects of application. Current Pediatrics. 2007;6:(1):137–140. (In Russ).Морозова С.В., Лусс Л.В. Хлоропирамин: современные аспекты применения // Вопросы современной педиатрии. 2007. Т. 6, № 1. С. 137–140.Goryachkina MV, Belousova TA. Chloropyramine: clinical aspects of application. Russian Medical Journal. Medical Review. 2014;22(24):1785–1789. (In Russ).Горячкина М.В., Белоусова Т.А. Хлоропирамин: клинические аспекты применения // Русский медицинский журнал. Медицинское обозрение. 2014. Т. 22, № 24. С. 1785–1789.Petrova KS, Petrova GA. Chloropyramine (suprastin) ― modern aspects of the use in the treatment of allergodermatoses. Russian Medical Journal. 2014;22(8):617–620. (In Russ).Петрова К.С., Петрова Г.А. Хлоропирамин (супрастин) ― современные аспекты применения в терапии аллергодерматозов // Русский медицинский журнал. 2014. Т. 22, № 8. С. 617–620.Revyakina VA. Antihistamines in clinical practice. Russian Medical Journal. 2014;22(11):854–856. (In Russ).Ревякина В.А. Антигистаминные препараты в клинической практике // Русский медицинский журнал. 2014. Т. 22, № 11. С. 854–856.Behrendt H, Ring J. Histamine, antihistamines and atopic eczema. Clin Exp Allergy. 1990;20(Suppl 4):25–30. doi: 10.1111/j.1365-2222.1990.tb02473.xBehrendt H., Ring J. Histamine, antihistamines and atopic eczema // Clin Exp Allergy. 1990. Vol. 20, Suppl 4. Р. 25–30. doi: 10.1111/j.1365-2222.1990.tb02473.xLangeland T, Fagertun HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. Allergy. 1994;49(1):22–26. doi: 10.1111/j.1398-9995.1994.tb00768.xLangeland T., Fagertun H.E., Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study // Allergy. 1994. Vol. 49, N 1. Р. 22–26. doi: 10.1111/j.1398-9995.1994.tb00768.xMonroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther. 1992;14(1):17–21.Monroe E.W. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis // Clin Ther 1992. Vol. 14, N 1. Р. 17–21.Popova IS, Matushevskaya EV, Svirshchevskaya EV. Double-blind placebo-controlled study of the efficacy and tolerability of clarotadine in atopic dermatitis. RMJ. 2001;9(4):477–483. (In Russ).Попова И.С., Матушевская Е.В., Свирщевская Е.В. Двойное слепое плацебоконтролируемое исследование эффективности и переносимости кларотадина при атопическом дерматите // РМЖ. 2001. Т. 9, № 4. С. 477–483.Hannuksela M, Kalimo K, Lammintausta K, et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy. 1993;70(2):127–133.Hannuksela M., Kalimo K., Lammintausta K., et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults // Ann Allergy. 1993. Vol. 70, N 2. Р. 127–133.La Rosa M, Ranno C, Musarra I, et al. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy. 1994;73(2):117–122.La Rosa M., Ranno C., Musarra I., et al. Double-blind study of cetirizine in atopic eczema in children // Ann Allergy. 1994. Vol. 73, N 2. Р. 117–122.Pavlova OV. Experience of using cetirizine (allertek) in the treatment of patients with atopic dermatitis and eczema. Bulletin of Dermatology and Venereology. 2005;(4):41–43. (In Russ).Павлова О.В. Опыт применения цетиризина (аллертека) в терапии больных атопическим дерматитом и экземой // Вестник дерматологии и венерологии. 2005. № 4. С. 41–43.Makarova IV, Zhiglinskaya OV, Mikhailova EA, Sukhorukova VG. Comparative efficacy of generic cetirizine (Egis production, Hungary) and original in the form of drops in the complex therapy of atopic dermatitis in young children. Current Pediatrics. 2007;6(3):85–88. (In Russ).Макарова И.В., Жиглинская О.В., Михайлова Е.А., Сухорукова В.Г. Сравнительная эффективность препаратов цетиризина дженерика (производство Эгис, Венгрия) и оригинального в форме капель в комплексной терапии атопического дерматита у детей раннего возраста // Вопросы современной педиатрии. 2007. Т. 6, № 3. С. 85–88.Samsygina GA. Allergic diseases in children. Moscow: GEOTAR-Media; 2019. 272 p. (In Russ).Самсыгина Г.А. Аллергические болезни у детей. Москва: ГЭОТАР-Медиа, 2019. 272 с.Delyagin VM, Urazbagambetov A. The use of Suprastinex (levocetirizine) in atopy in children and adolescents. Russian Medical Journal. 2012;20(16):828–830. (In Russ).Делягин В.М., Уразбагамбетов А. Применение Cупрастинекса (левоцетиризина) при атопии у детей и подростков // Русский медицинский журнал. 2012. Т. 20, № 16. C. 828–830.Elisyutina OG, Fedenko ES, Fedoskova TG, Luss LV. Efficacy of levocetirizine therapy in patients with allergodermatoses. Russian Journal of Allergy. 2012;(5):69–75. (In Russ).Елисютина О.Г., Феденко Е.С., Федоскова Т.Г., Лусс Л.В. Эффективность терапии левоцетиризином больных с аллергодерматозами // Российский аллергологический журнал. 2012. № 5. C. 69–75.Tamrazova OB. Pathogenetic therapy of children suffering from severe forms of atopic dermatitis. Russian Medical Journal. 2013;(2):108–114. (In Russ).Тамразова О.Б. Патогенетическая терапия детей, страдающих тяжелыми формами атопического дерматита // Русский медицинский журнал. 2013. № 2. C. 108–114.Nazhmutdinova DK, Shvets OI. Levocetirizine: reboot. Russian Medical Journal. 2011;19(21):1324–1326. (In Russ).Нажмутдинова Д.К., Швец О.И. Левоцетиризин: перезагрузка // Русский медицинский журнал. 2011. Т. 19, № 21. C. 1324–1326.Kamaev AV, Trusova OV, Kamaeva IA. Itching in atopic dermatitis in children: known mechanisms and possibilities of its long-term control. Russian Medical Journal. 2015;23(3):142–146. (In Russ).Камаев А.В., Трусова О.В., Камаева И.А. Зуд при атопическом дерматите у детей: известные механизмы и возможности его долгосрочного контроля // Русский медицинский журнал. 2015. Т. 23, № 3. C. 142–146.Monakhov SA, Korzhachkina NB, Olisova OYu. Narrow-wave phototherapy 311 nm in the treatment of patients with atopic dermatitis. Russian Journal of Skin and Venereal Diseases. 2012;(3):25–27. (In Russ).Монахов С.А., Коржачкина Н.Б., Олисова О.Ю. Узковолновая фототерапия 311 нм в лечении больных атопическим дерматитом // Российский журнал кожных и венерических болезней. 2012. № 3. C. 25–27.Majoie IM, Oldhoff JM, van Weelden H, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2009;60(1):77–84. doi: 10.1016/j.jaad.2008.08.048Majoie I.M., Oldhoff J.M., van Weelden H., et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis // J Am Acad Dermatol. 2009. Vol. 60, N 1. Р. 77–84. doi: 10.1016/j.jaad.2008.08.048Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet. 2001;357(9273):2012–2016. doi: 10.1016/S0140-6736(00)05114-XReynolds N.J., Franklin V., Gray J.C., et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial // Lancet. 2001. Vol. 357, N 9273. Р. 2012–2016. doi: 10.1016/S0140-6736(00)05114-XClayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2007;32(1):28–33.Clayton T.H., Clark S.M., Turner D., Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy // Clin Exp Dermatol. 2007. Vol. 32, N 1. Р. 28–33.Seccombe L, Wynne MD, Clancy C, et al. A retrospective review of phototherapy in children, at a tertiary paediatric dermatology unit. Photodermatol Photoimmunol Photomed. 2021;37(1):34–38.Seccombe L., Wynne M.D., Clancy C., et al. A retrospective review of phototherapy in children, at a tertiary paediatric dermatology unit // Photodermatol Photoimmunol Photomed. 2021. Vol. 37, N 1. Р. 34–38.Gambichler T, Othlinghaus N, Tomi NS, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol. 2009;160(3):652–658. doi: 10.1111/j.1365-2133.2008.08984.xGambichler T., Othlinghaus N., Tomi N.S., et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study // Br J Dermatol. 2009. Vol. 160, N 3. Р. 652–658. doi: 10.1111/j.1365-2133.2008.08984.xBogaczewicz J, Malinowska K, Sysa-Jedrzejowska A, Wozniacka A. Medium-dose ultraviolet A1 phototherapy improves SCORAD index and increases mRNA expression of interleukin-4 without direct effect on human β defensin-1, interleukin-10, and interleukin-31. Int J Dermatol. 2016;55(7):e380–385. doi: 10.1111/ijd.13213Bogaczewicz J., Malinowska K., Sysa-Jedrzejowska A., Wozniacka A. Medium-dose ultraviolet A1 phototherapy improves SCORAD index and increases mRNA expression of interleukin-4 without direct effect on human β defensin-1, interleukin-10, and interleukin-31 // Int J Dermatol. 2016. Vol. 55, N 7. Р. e380–385. doi: 10.1111/ijd.13213Tzaneva S, Seeber A, Schwaiger M, et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol. 2001;45:503–507.TzanevaS., Seeber A., Schwaiger M., et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis // J Am Acad Dermatol. 2001. Vol. 45. Р. 503–507.Malinowska K, Wozniacka A, Bogaczewicz J. The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis. Postepy Dermatol Alergol. 2020;37(6):962–967.Malinowska K., Wozniacka A., Bogaczewicz J. The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis // Postepy Dermatol Alergol. 2020. Vol. 37, N 6. Р. 962–967.Abeck D, Schmidt T, Fesq H, et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol. 2000;42 (2 Pt 1):254–257.Abeck D., Schmidt T., Fesq H., et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis // J Am Acad Dermatol. 2000. Vol. 42, N 2, Pt 1. Р. 254–257.Pugashetti R, Lim HW, Koo J. Broadband UVB revisited: is the narrowband UVB fad limiting our therapeutic options? J Dermatolog Treat. 2010;21(6):326–330. doi: 10.3109/09546630903341986Pugashetti R., Lim H.W., Koo J. Broadband UVB revisited: is the narrowband UVB fad limiting our therapeutic options? // J Dermatolog Treat. 2010. Vol. 21, N 6. Р. 326–330. doi: 10.3109/09546630903341986Tzaneva S, Kittler H, Holzer G, et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol. 2010;162(3):655–660. doi: 10.1111/j.1365-2133.2009.09514.xTzaneva S., Kittler H., Holzer G., et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial // Br J Dermatol. 2010. Vol. 162, N 3. Р. 655–660. doi: 10.1111/j.1365-2133.2009.09514.xGarritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol. 2014;170(3):501–513. doi: 10.1111/bjd.12645Garritsen F.M., Brouwer M.W., Limpens J., Spuls P.I. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research // Br J Dermatol. 2014. Vol. 170, N 3. P. 501–513. doi: 10.1111/bjd.12645Pérez-Ferriols A, Aranegui B, Pujol-Montcusí JA, et al. Phototherapy in atopic dermatitis: a systematic review of the literature. Actas Dermosifiliogr. 2015;106(5):387–401. doi: 10.1016/j.ad.2014.12.017Pérez-Ferriols A., Aranegui B., Pujol-Montcusí J.A., et al. Phototherapy in atopic dermatitis: a systematic review of the literature // Actas Dermosifiliogr. 2015. Vol. 106, N 5. P. 387–401. doi: 10.1016/j.ad.2014.12.017Uetsu N, Horio T. Treatment of persistent severe atopic dermatitis in 113 Japanese patients with oral psoralen photo-chemotherapy. J Dermatol. 2003;30(6):450–457. doi: 10.1111/j.1346-8138.2003.tb00415.xUetsu N., Horio T. Treatment of persistent severe atopic dermatitis in 113 Japanese patients with oral psoralen photo-chemotherapy // J Dermatol. 2003. Vol. 30, N 6. P. 450–457. doi: 10.1111/j.1346-8138.2003.tb00415.xPhysical and rehabilitation medicine. The National Guide. Ed. by G.N. Ponomarenko. Moscow: GEOTAR-Media; 2016. 688 p. (In Russ).Физическая и реабилитационная медицина. Национальное руководство / под ред. Г.Н. Пономаренко. Москва: ГЭОТАР-Медиа, 2016. 688 с.Private physiotherapy: A textbook. Ed. by G.N. Ponomarenko. Moscow: Meditsina; 2005. 744 p. (In Russ).Частная физиотерапия: Учебное пособие / под ред. Г.Н. Пономаренко. Москва: Медицина, 2005. 744 с.Patrizi A, Raone B, Ravaioli GM. Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol. 2015;(8):511–520. doi: 10.2147/CCID.S87987Patrizi A., Raone B., Ravaioli G.M. Management of atopic dermatitis: safety and efficacy of phototherapy // Clin Cosmet Investig Dermatol. 2015. Vol. 8. Р. 511–520. doi: 10.2147/CCID.S87987Dogra S, Mahajan R. Indian Association of Dermatologists, Venereologists and Leprologists. Phototherapy for atopic dermatitis. Indian J Dermatol Venereol Leprol. 2015;81(1):10–15. doi: 10.4103/0378-6323.148557Dogra S., Mahajan R. Indian Association of Dermatologists, Venereologists and Leprologists. Phototherapy for atopic dermatitis // Indian J Dermatol Venereol Leprol. 2015. Vol. 81, N 1. Р. 10–15. doi: 10.4103/0378-6323.148557Kubanova AA, Samsonov VA, Volnukhin VA, et al. Therapy of patients with psoriasis, atopic dermatitis and vitiligo with narrow-band medium-wave ultraviolet radiation with a wavelength of 311 nm. Medical technology No. FS-2006/250 of August 15, 2006. Bulletin of Dermatology and Venereology. 2008;(3):17–20. (In Russ).Кубанова А.А., Самсонов В.А., Волнухин В.А., и др. Терапия больных псориазом, атопическим дерматитом и витилиго узкополосным средневолновым ультрафиолетовым излучением с длиной волны 311 нм. Медицинская технология № ФС-2006/250 от 15 августа 2006 года // Вестник дерматологии и венерологии. 2008. № 3. С. 17–20.Thompson KG, Kim N. Distinguishing myth from fact: photocarcinogenesis and phototherapy. Dermatol Clin. 2020;38(1):25–35. doi: 10.1016/j.det.2019.08.003Thompson K.G., Kim N. Distinguishing myth from fact: photocarcinogenesis and phototherapy // Dermatol Clin. 2020. Vol. 38, N 1. Р. 25–35. doi: 10.1016/j.det.2019.08.003Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293.Paller A.S., Siegfried E.C., Thaçi D., et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial // J Am Acad Dermatol. 2020. Vol. 83, N 5. Р. 1282–1293.Paller AS, Bansal A, Simpson EL, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: Post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020;21(1):119–131.Paller A.S., Bansal A., Simpson E.L., et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: Post-hoc analyses from a randomized clinical trial // Am J Clin Dermatol. 2020. Vol. 21, N 1. Р. 119–131.Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56.Simpson E.L., Paller A.S., Siegfried E.C., et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial // JAMA Dermatol. 2020. Vol. 156, N 1. Р. 44–56.Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020;182(1):85–96.Cork M.J., Thaçi D., Eichenfield L.F., et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension // Br J Dermatol. 2020. Vol. 182, N 1. Р. 85–96.Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020Simpson E.L., Bieber T., Guttman-Yassky E., et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis // N Engl J Med. 2016. Vol. 375, N 24. Р. 2335–2348. doi: 10.1056/NEJMoa1610020Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi: 10.1016/S0140-6736(17)31191-1Blauvelt A., de Bruin-Weller M., Gooderham M., et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial // Lancet. 2017. Vol. 389, N 10086. Р. 2287–2303. doi: 10.1016/S0140-6736(17)31191-1De Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–1101. doi: 10.1111/bjd.16156De Bruin-Weller M., Thaçi D., Smith C.H., et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) // Br J Dermatol. 2018. Vol. 178, N 5. Р. 1083–1101. doi: 10.1111/bjd.16156Thaçi D, L Simpson E, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266–275. doi: 10.1016/j.jdermsci.2019.02.002Thaçi D., L Simpson E., Deleuran M., et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2) // J Dermatol Sci. 2019. Vol. 94, N 2. Р. 266–275. doi: 10.1016/j.jdermsci.2019.02.002Cork MJ, Eckert L, Simpson EL, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2020;31(6):606–614. doi: 10.1080/09546634.2019.1612836Cork M.J., Eckert L., Simpson E.L., et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2 // J Dermatolog Treat. 2020. Vol. 31, N 6. Р. 606–614. doi: 10.1080/09546634.2019.1612836Snast I, Reiter O, Hodak E, et al. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(2):145–165. doi: 10.1007/s40257-017-0324-7Snast I., Reiter O., Hodak E., et al. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis // Am J Clin Dermatol. 2018. Vol. 19, N 2. Р. 145–165. doi: 10.1007/s40257-017-0324-7Wang FP, Tang XJ, Wei CQ, et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci. 2018;90(2):190–198. doi: 10.1016/j.jdermsci.2018.01.016Wang F.P., Tang X.J., Wei C.Q., et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis // J Dermatol Sci. 2018. Vol. 90, N 2. Р. 190–198. doi: 10.1016/j.jdermsci.2018.01.016Czech W, Brautigam M, Weidinger G, Schöpf E. Body weight independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol. 2000;42(4):653–659.Czech W., Brautigam M., Weidinger G., Schöpf E. Body weight independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life // J Am Acad Dermatol. 2000. Vol. 42, N 4. Р. 653–659.Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142(1):52–58. doi: 10.1046/j.1365-2133.2000.03241.xHarper J.I., Ahmed I., Barclay G., et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy // Br J Dermatol 2000. Vol. 142, N 1. Р. 52–58. doi: 10.1046/j.1365-2133.2000.03241.xGranlund H, Erkko P, Remitz A, et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm Venereol. 2001;81(1):22–27. doi: 10.1080/00015550120235Granlund H., Erkko P., Remitz A., et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis // Acta Derm Venereol 2001. Vol. 81, N 1. Р. 22–27. doi: 10.1080/00015550120235Zurbriggen B, Wuthrich B, Cachelin AB, et al. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. Dermatology. 1999;198(1):56–60. doi: 10.1159/000018065Zurbriggen B., Wuthrich B., Cachelin A.B., et al. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study // Dermatology. 1999. Vol. 198, N 1. Р. 56–60. doi: 10.1159/000018065Hijnen DJ, Ten Berge O, Timmer-de Mik L, et al. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol. 2007;21(1):85–89. doi: 10.1111/j.1468-3083.2006.01877.xHijnen D.J., Ten Berge O., Timmer-de Mik L., et al. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis // J Eur Acad Dermatol Venereol. 2007. Vol. 21, N 1. Р. 85–89. doi: 10.1111/j.1468-3083.2006.01877.xSchmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21(5):606–619. doi: 10.1111/j.1468-3083.2006.02023.xSchmitt J., Schmitt N., Meurer M. Cyclosporin in the treatment of patients with atopic eczema a systematic review and meta-analysis // J Eur Acad Dermatol Venereol. 2007. Vol. 21, N 5. Р. 606–619. doi: 10.1111/j.1468-3083.2006.02023.xAmor KT, Ryan K, Menter A. The use of cyclosporine in dermatology: Part I. J Am Acad Dermatol. 2010;63(6):925–946. quiz 947-948. doi: 10.1016/j.jaad.2010.02.063Amor K.T., Ryan K., Menter A. The use of cyclosporine in dermatology: Part I // J Am Acad Dermatol. 2010. Vol. 63, N 6. Р. 925–946. quiz 947-948. doi: 10.1016/j.jaad.2010.02.063Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. doi: 10.1111/jdv.14888Wollenberg A., Barbarot S., Bieber T., et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II // J Eur Acad Dermatol Venereol. 2018. Vol. 32, N 6. Р. 850–878. doi: 10.1111/jdv.14888Shamov BA. Atopic dermatitis: clinical manifestations and treatment. Diary of the Kazan Medical School. 2014;(1):63–65. (In Russ).Шамов Б.А. Атопический дерматит: клинические проявления и лечение // Дневник Казанской медицинской школы. 2014. № 1. C. 63–65.Jung MY, Chung JY, Lee HY, et al. Antibiotic susceptibility of Staphylococcus aureus in atopic dermatitis: current prevalence of methicillin-resistant Staphylococcus aureus in Korea and treatment strategies. Ann Dermatol. 2015;27(4):398–403. doi: 10.5021/ad.2015.27.4.398Jung M.Y., Chung J.Y., Lee H.Y., et al. Antibiotic susceptibility of Staphylococcus aureus in atopic dermatitis: current prevalence of methicillin-resistant Staphylococcus aureus in Korea and treatment strategies // Ann Dermatol. 2015. Vol. 27, N 4. Р. 398–403. doi: 10.5021/ad.2015.27.4.398Lübbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol. 2003;4(9):641–654. doi: 10.2165/00128071-200304090-00006Lübbe J. Secondary infections in patients with atopic dermatitis // Am J Clin Dermatol. 2003. Vol. 4, N 9. Р. 641–654. doi: 10.2165/00128071-200304090-00006Masyukova SA, Gladko EV, Tarasenko GN, et al. Fusidic acid in the treatment of pyodermatitis and allergodermatoses complicated by bacterial infection. Bulletin of Dermatology and Venereology. 2007;(6):54–57. (In Russ).Масюкова С.А., Гладько Е.В., Тарасенко Г.Н. и др. Фузидиевая кислота в лечении пиодермитов и аллергодерматозов, осложненных бактериальной инфекцией // Вестник дерматологии и венерологии. 2007. № 6. С. 54–57.Dvoryankova EV, Korsunskaya IM, Zakharova AB, Zhukovsky RO. Atopic dermatitis complicated by secondary infection: approaches to therapy. Effective Pharmacotherapy. 2011;(26):74–76. (In Russ).Дворянкова Е.В., Корсунская И.М., Захарова А.Б., Жуковский Р.О. Атопический дерматит, осложненный вторичной инфекцией: подходы к терапии // Эффективная фармакотерапия. 2011. № 26. С. 74–76.Larkova IA. Effective therapy of atopic dermatitis in children complicated by secondary infection. Medical Advice. 2016;(1):162–167. (In Russ). doi: 10.21518/2079-701X-2016-1-162-167Ларькова И.А. Эффективная терапия атопического дерматита у детей, осложненного вторичной инфекцией // Медицинский совет. 2016. № 1. С. 162–167. doi: 10.21518/2079-701X-2016-1-162-167Matushevskaya EV, Svirshchevskaya EV. Atopic dermatitis in the practice of a dermatovenerologist: a rational choice of therapy. Russian Medical Journal. 2013;21(8):410–412. (In Russ).Матушевская Е.В., Свирщевская Е.В. Атопический дерматит в практике врача-дерматовенеролога: рациональный выбор терапии // Русский медицинский журнал. 2013. Т. 21, № 8. С. 410–412.Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006;155(4):680–687. doi: 10.1111/j.1365-2133.2006.07410.xGong J.Q., Lin L., Lin T., et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial // Br J Dermatol. 2006. Vol. 155, N 4. Р. 680–687. doi: 10.1111/j.1365-2133.2006.07410.xLever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol. 1988;119(2):189–198. doi: 10.1111/j.1365-2133.1988.tb03201.xLever R., Hadley K., Downey D., Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy // Br J Dermatol. 1988. Vol. 119, N 2. Р. 189–198. doi: 10.1111/j.1365-2133.1988.tb03201.xAlbanova V. External treatment of atopic dermatitis. Doctor. 2006;(2):76–78.Альбанова В. Наружное лечение атопического дерматита // Врач. 2006. № 2. С. 76–78.Batyrshina SV, Khaertdinova LA. The concept of local therapy of patients with atopic dermatitis. Practical Medicine. 2009;35(3):41–45.Батыршина С.В., Хаертдинова Л.А. Концепция местной терапии больных атопическим дерматитом // Практическая медицина. 2009. Т. 35, № 3. С. 41–45.Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol. 1976;95(3):323–328. doi: 10.1111/j.1365-2133.1976.tb07021.xWachs G.N., Maibach H.I. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis // Br J Dermatol. 1976. Vol. 95, N 3. Р. 323–328. doi: 10.1111/j.1365-2133.1976.tb07021.xSchuttelaar ML, Coenraads PJ. A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(9):1076–1082. doi: 10.1111/j.1468-3083.2008.02716.xSchuttelaar M.L., Coenraads P.J. A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis // J Eur Acad Dermatol Venereol. 2008. Vol. 22, N 9. Р. 1076–1082. doi: 10.1111/j.1468-3083.2008.02716.xVasenova VYu, Butov YuS. The use of Polcortolone TS for the treatment of itchy dermatoses complicated by secondary infection. Russian Medical Journal. 2013;21(22):1096–1098. (In Russ).Васенова В.Ю., Бутов Ю.С. Применение Полькортолона ТС для лечения зудящих дерматозов, осложненных вторичной инфекцией // Русский медицинский журнал. 2013. Т. 21, № 22. С. 1096–1098.Skripkin YuK, Khamaganova IV. Experience of using oxycort and polcortolon TS aerosols in the treatment of allergic dermatoses complicated by pyoderma. Bulletin of Dermatology and Venereology. 2004;(1):42–43. (In Russ).Скрипкин Ю.К., Хамаганова И.В. Опыт применения аэрозолей оксикорт и полькортолон ТС в лечении аллергических дерматозов, осложненных пиодермией // Вестник дерматологии и венерологии. 2004. № 1. С. 42–43.Ramsay C, Savoie J, Gilbert M, et al. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol. 1996;7(Suppl. 1):S15–22. doi: 10.1016/0926-9959(96)00032-3Ramsay C., Savoie J., Gilbert M., et al. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate // J Eur Acad Dermatol Venereol. 1996. Vol. 7, Suppl. 1. Р. S15–22. doi: 10.1016/0926-9959(96)00032-3Hjorth N, Schmidt H, Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica. 1985;4(1):126–131.Hjorth N., Schmidt H., Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema // Pharmatherapeutica. 1985. Vol. 4, N 1. Р. 126–131.Tarasova MV, Marina TV, Sorokina EA, et al. The expediency of using combined topical glucocorticosteroids in the complex therapy of atopic dermatitis. Health and Education in the XXI century. 2008;10(3):383. (In Russ).Тарасова М.В., Марина Т.В., Сорокина Е.А., и др. Целесообразность применения комбинированных топических глюкокортикостероидов в комплексной терапии атопического дерматита // Здоровье и образование в XXI веке. 2008. Т. 10, № 3. С. 383.Kubanova AA, Proshutinskaya DV, Tekucheva LV, Avdienko IN. Integral approach to external therapy of patients with atopic dermatitis. Bulletin of Dermatology and Venereology. 2010;(1):20–26. (In Russ).Кубанова А.А., Прошутинская Д.В., Текучева Л.В., Авдиенко И.Н. Интегральный подход к наружной терапии больных атопическим дерматитом // Вестник дерматологии и венерологии. 2010. № 1. С. 20–26.Nenasheva NM. Features of local (external) therapy of atopic dermatitis complicated by infection. RMJ. 2015;23(19):1159–1165. (In Russ).Ненашева Н.М. Особенности местной (наружной) терапии осложненного инфекцией атопического дерматита // РМЖ. 2015. Т. 23, № 19. С. 1159–1165.Kungurov NV, Keniksfest YuV, Kohan MM, et al. Combined external therapy of complicated dermatoses. Clinical Dermatology and Venereology. 2005;(2):33–37. (In Russ).Кунгуров Н.В., Кениксфест Ю.В., Кохан М.М., и др. Комбинированная наружная терапия осложненных дерматозов // Клиническая дерматология и венерология. 2005. № 2. С. 33–37.Niebuhr M, Mai U, Kapp A, Werfel T. Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities. Exp Dermatol. 2008;17(11):953–957. doi: 10.1111/j.1600-0625.2008.00734.xNiebuhr M., Mai U., Kapp A., Werfel T. Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities // Exp Dermatol. 2008. Vol. 17, N 11. Р. 953–957. doi: 10.1111/j.1600-0625.2008.00734.xBoguniewicz M, Sampson H, Leung S, et al. Effects of cefuroxime axetil on Staphylococcus aureus colonizing and superantigen production in atopic dermatitis. J Allergy Clin Immunol. 2001;108(4):651–652. doi: 10.1067/mai.2001.118598Boguniewicz M., Sampson H., Leung S., et al. Effects of cefuroxime axetil on Staphylococcus aureus colonizing and superantigen production in atopic dermatitis // J Allergy Clin Immunol. 2001. Vol. 108, N 4. Р. 651–652. doi: 10.1067/mai.2001.118598Treneva MS, Pampura AN. Strategy of choosing antibacterial drugs in children with microbial infection of atopic dermatitis. Practical Medicine. 2011;(3):136–139. (In Russ).Тренева М.С., Пампура А.Н. Стратегия выбора антибактериальных препаратов у детей с микробным инфицированием атопического дерматита // Практическая медицина. 2011. № 3. С. 136–139.Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125(1):4–13. quiz 14-15. doi: 10.1016/j.jaci.2009.11.027Boguniewicz M., Leung D.Y. Recent insights into atopic dermatitis and implications for management of infectious complications // J Allergy Clin Immunol. 2010. Vol. 125, N 1. Р. 4–13. quiz 14-15. doi: 10.1016/j.jaci.2009.11.027Tognetti L, Martinelli C, Berti S, et al. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: a collaboration between dermatologists and infectivologists. J Eur Acad Dermatol Venereol. 2012;26(8):931–941. doi: 10.1111/j.1468-3083.2011.04416.xTognetti L., Martinelli C., Berti S., et al. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: a collaboration between dermatologists and infectivologists // J Eur Acad Dermatol Venereol. 2012. Vol. 26, N 8. Р. 931–941. doi: 10.1111/j.1468-3083.2011.04416.xPetry V, Bessa GR, Poziomczyck CS, et al. Bacterial skin colonization and infections in patients with atopic dermatitis. An Bras Dermatol. 2012;87(5):729–734. doi: 10.1590/s0365-05962012000500010Petry V., Bessa G.R., Poziomczyck C.S., et al. Bacterial skin colonization and infections in patients with atopic dermatitis // An Bras Dermatol. 2012. Vol. 87, N 5. Р. 729–734. doi: 10.1590/s0365-05962012000500010Wollenberg A. Eczema herpeticum. Chem Immunol Allergy. 2012;(96):89–95. doi: 10.1159/000331892Wollenberg A. Eczema herpeticum // Chem Immunol Allergy. 2012. Vol. 96. Р. 89–95. doi: 10.1159/000331892Niimura M, Nishikawa T. Treatment of eczema herpeticum with oral acyclovir. Am J Med.1988;85(2A):49–52.Niimura M., Nishikawa T. Treatment of eczema herpeticum with oral acyclovir // Am J Med.1988. Vol. 85, N 2A. Р. 49–52.Bussmann C, Bockenhoff A, Henke H, et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol. 2006;118(6):1292–1298. doi: 10.1016/j.jaci.2006.07.054Bussmann C., Bockenhoff A., Henke H., et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? // J Allergy Clin Immunol. 2006. Vol. 118, N 6. Р. 1292–1298. doi: 10.1016/j.jaci.2006.07.054Darsow U, Forer I, Ring J. Allergen-specific immunotherapy in atopic eczema. Curr Allergy Asthma Rep. 2011;11(4):277–283. doi: 10.1007/s11882-011-0194-7Darsow U., Forer I., Ring J. Allergen-specific immunotherapy in atopic eczema // Curr Allergy Asthma Rep. 2011. Vol. 11, N 4. Р. 277–283. doi: 10.1007/s11882-011-0194-7Bae JM, Choi YY, Park CO, et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132(1):110–117. doi: 10.1016/j.jaci.2013.02.044Bae J.M., Choi Y.Y., Park C.O., et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials // J Allergy Clin Immunol. 2013. Vol. 132, N 1. Р. 110–117. doi: 10.1016/j.jaci.2013.02.044Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol. 1982;107(5):597–602. doi: 10.1111/j.1365-2133.1982.tb00412.xRing J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins // Br J Dermatol. 1982. Vol. 107, N 5. Р. 597–602. doi: 10.1111/j.1365-2133.1982.tb00412.xGlover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992;22(4):440–446. doi: 10.1111/j.1365-2222.1992.tb00145.xGlover M.T., Atherton D.J. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema // Clin Exp Allergy. 1992. Vol. 22, N 4. Р. 440–446. doi: 10.1111/j.1365-2222.1992.tb00145.xZachariae H, Cramers M, Herlin T, et al. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1985;(114):48–54. doi: 10.2340/000155551144854Zachariae H., Cramers M., Herlin T., et al. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis // Acta Derm Venereol Suppl (Stockh). 1985. Vol. 114. Р. 48–54. doi: 10.2340/000155551144854Yelisyutina OG, Fedenko ES. The place of specific immunotherapy in the treatment of patients with atopic dermatitis complicated by recurrent pyoderma. Physiology and Pathology of the Immune System. 2006;(8):15. (In Russ).Елисютина О.Г., Феденко Е.С. Место специфической иммунотерапии в лечении больных атопическим дерматитом, осложненным рецидивирующей пиодермией // Физиология и патология иммунной системы. 2006. № 8. С. 15.Novak N, Bieber T, Hoffmann M, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol. 2012;130(4):925– 931e4. doi: 10.1016/j.jaci.2012.08.004Novak N., Bieber T., Hoffmann M., et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis // J Allergy Clin Immunol. 2012. Vol. 130, N 4. Р. 925– 931e4. doi: 10.1016/j.jaci.2012.08.004Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120(1):164–170. doi: 10.1016/j.jaci.2007.04.008Pajno G.B., Caminiti L., Vita D., et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study // J Allergy Clin Immunol. 2007. Vol. 120, N 1. Р. 164–170. doi: 10.1016/j.jaci.2007.04.008Qin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. Int J Dermatol. 2014;53(5):650–655. doi: 10.1111/ijd.12302Qin Y.E., Mao J.R., Sang Y.C., Li W.X. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis // Int J Dermatol. 2014. Vol. 53, N 5. Р. 650–655. doi: 10.1111/ijd.12302Liu L, Guo D, Liang Q, et al. The efficacy of sublingual immunotherapy with Dermatophagoides farinae vaccine in a murine atopic dermatitis model. Clin Exp Allergy. 2015;45(4):815–822. doi: 10.1111/cea.12417Liu L., Guo D., Liang Q., et al. The efficacy of sublingual immunotherapy with Dermatophagoides farinae vaccine in a murine atopic dermatitis model // Clin Exp Allergy. 2015. Vol. 45, N 4. Р. 815–822. doi: 10.1111/cea.12417Roduit C, Frei R, Loss G, et al. Development of atopic dermatitis according to age of onset and association with early-life exposures. J Allergy Clin Immunol. 2012;130(1):130–136e5. doi: 10.1016/j.jaci.2012.02.043Roduit C., Frei R., Loss G., et al. Development of atopic dermatitis according to age of onset and association with early-life exposures // J Allergy Clin Immunol. 2012. Vol. 130, N 1. Р. 130–136 e5. doi: 10.1016/j.jaci.2012.02.043Perkin MR, Logan K, Tseng A, et al. Randomized trial of introduction of allergenic foods in breast-fed infants. N Engl J Med. 2016;374(18):1733–1743. doi: 10.1056/NEJMoa1514210Perkin M.R., Logan K., Tseng A., et al. Randomized trial of introduction of allergenic foods in breast-fed infants // N Engl J Med. 2016. Vol. 374, N 18. Р. 1733–1743. doi: 10.1056/NEJMoa1514210Prell C, Koletzko B. Breastfeeding and complementary feeding. Dtsch Arztebl Int. 2016;113(25):435–444. doi: 10.3238/arztebl.2016.0435Prell C., Koletzko B. Breastfeeding and complementary feeding // Dtsch Arztebl Int. 2016. Vol. 113, N 25. Р. 435–444. doi: 10.3238/arztebl.2016.0435Vandenplas Y, Al-Hussaini B, Al-Mannaei K, et al. Prevention of allergic sensitization and treatment of cow’s milk protein allergy in early life: the middle-east step-down consensus. Nutrients. 2019;11(7):1444. doi: 10.3390/nu11071444Vandenplas Y., Al-Hussaini B., Al-Mannaei K., et al. Prevention of allergic sensitization and treatment of cow’s milk protein allergy in early life: the middle-east step-down consensus // Nutrients. 2019. Vol. 11, N 7. Р. 1444. doi: 10.3390/nu11071444Gruber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects. Exp Rev Clin Immunol. 2012;8(1):17–19. doi: 10.1586/eci.11.74Gruber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects // Exp Rev Clin Immunol. 2012. Vol. 8, N 1. Р. 17 –19. doi: 10.1586/eci.11.74Cuello-Garcia CA, Brozek JL, Fiocchi A, et al. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2015;136(4):952–961. doi: 10.1016/j.jaci.2015.04.031Cuello-Garcia C.A., Brozek J.L., Fiocchi A., et al. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials // J Allergy Clin Immunol. 2015. Vol. 136, N 4. Р. 952–961. doi: 10.1016/j.jaci.2015.04.031Panduru М, Panduru NM, Sălăvăstru CM, Tiplica GS. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol. 2015;29(2):232–242. doi: 10.1111/jdv.12496Panduru М., Panduru N.M., Sălăvăstru C.M., Tiplica G.S. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies // J Eur Acad Dermatol Venereol. 2015. Vol. 29, N 2. Р. 232–242. doi: 10.1111/jdv.12496Muraro A, Halken S, Arshad SH, et al. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy. 2014;69(5):590–601. doi: 10.1111/all.12398Muraro A., Halken S., Arshad S.H., et al. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy // Allergy. 2014. Vol. 69, N 5. Р. 590–601. doi: 10.1111/all.12398Kantor R, Kim A, Thyssen JP, Silverberg JI. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. J Am Acad Dermatol. 2016;75(6):1119–1125e1. doi: 10.1016/j.jaad.2016.07.017Kantor R., Kim A., Thyssen J.P., Silverberg J.I. Association of atopic dermatitis with smoking: a systematic review and meta-analysis // J Am Acad Dermatol. 2016. Vol. 75, N 6. Р. 1119–1125e1. doi: 10.1016/j.jaad.2016.07.017Kathuria P, Silverberg JI. Association of pollution and climate with atopic eczema in US children. Pediatr Allergy Immunol. 2016;27(5):478–485. doi: 10.1111/pai.12543Kathuria P., Silverberg J.I. Association of pollution and climate with atopic eczema in US children // Pediatr Allergy Immunol. 2016. Vol. 27, N 5. Р. 478–485. doi: 10.1111/pai.12543Morgenstern V, Zutavern A, Cyrys J, et al. Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children. Am J Respir Crit Care Med. 2008;177(12):1331–1337. doi: 10.1164/rccm.200701-036OCMorgenstern V., Zutavern A., Cyrys J., et al. Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children // Am J Respir Crit Care Med. 2008. Vol. 177, N 12. Р. 1331–1337. doi: 10.1164/rccm.200701-036OCHidaka T, Ogawa E, Kobayashi EH, et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. Nat Immunol. 2017;18(1):64–73. doi: 10.1038/ni.3614Hidaka T., Ogawa E., Kobayashi E.H., et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin // Nat Immunol. 2017. Vol. 18, N 1. Р. 64–73. doi: 10.1038/ni.3614Ricci G, Bendandi B, Aiazzi R, et al. Three years of Italian experience of an educational program for parents of young children affected by atopic dermatitis: improving knowledge produces lower anxiety levels in parents of children with atopic dermatitis. Pediatr Dermatol. 2009;26(1):1–5. doi: 10.1111/j.1525-1470.2008.00813.xRicci G., Bendandi B., Aiazzi R., et al. Three years of Italian experience of an educational program for parents of young children affected by atopic dermatitis: improving knowledge produces lower anxiety levels in parents of children with atopic dermatitis // Pediatr Dermatol. 2009. Vol. 26, N 1. Р. 1–5. doi: 10.1111/j.1525-1470.2008.00813.xStaab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006;332(7547):933–938. doi: 10.1136/bmj.332.7547.933Staab D., Diepgen T.L., Fartasch M., et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial // BMJ. 2006. Vol. 332, N 7547. Р. 933–938. doi: 10.1136/bmj.332.7547.933Lambert J, Bostoen J, Geusens B, et al. A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results. Arch Dermatol Res. 2011;303(1):57–63. doi: 10.1007/s00403-010-1082-zLambert J., Bostoen J., Geusens B., et al. A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results // Arch Dermatol Res. 2011. Vol. 303, N 1. Р. 57–63. doi: 10.1007/s00403-010-1082-zKupfer J, Gieler U, Diepgen TL, et al. Structured education program improves the coping with atopic dermatitis in children and their parents-a multicenter, randomized controlled trial. J Psychosom Res. 2010;68(4):353–358. doi: 10.1016/j.jpsychores.2009.04.014Kupfer J., Gieler U., Diepgen T.L., et al. Structured education program improves the coping with atopic dermatitis in children and their parents-a multicenter, randomized controlled trial // J Psychosom Res. 2010. Vol. 68, N 4. Р. 353–358. doi: 10.1016/j.jpsychores.2009.04.014Staab D, von Rueden U, Kehrt R, et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. Pediatr Allergy Immunol. 2002;13(2):84–90. doi: 10.1034/j.1399-3038.2002.01005.xStaab D., von Rueden U., Kehrt R., et al. Evaluation of a parental training program for the management of childhood atopic dermatitis // Pediatr Allergy Immunol. 2002. Vol. 13, N 2. Р. 84–90. doi: 10.1034/j.1399-3038.2002.01005.x VeienKiriyama T, Sugiura H, Uehara M. Residual washing detergent in cotton clothes: a factor of winter deterioration of dry skin in atopic dermatitis. J Dermatol. 2003;30(10):708–712. doi: 10.1111/j.1346-8138.2003.tb00463.xKiriyama T., Sugiura H., Uehara M. Residual washing detergent in cotton clothes: a factor of winter deterioration of dry skin in atopic dermatitis // J Dermatol. 2003. Vol. 30, N 10. Р. 708–712. doi: 10.1111/j.1346-8138.2003.tb00463.xSchmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol. 2006;19(6):296–302. doi: 10.1159/000094670Schmid-Wendtner M.H., Korting H.C. The pH of the skin surface and its impact on the barrier function // Skin Pharmacol Physiol. 2006. Vol. 19, N 6. Р. 296–302. doi: 10.1159/000094670Simpson E, Trookman NS, Rizer RL, et al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. Pediatr Dermatol. 2012;29(5):590–597. doi: 10.1111/j.1525-1470.2012.01809.xSimpson E., Trookman N.S., Rizer R.L., et al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study // Pediatr Dermatol. 2012. Vol. 29, N 5. Р. 590–597. doi: 10.1111/j.1525-1470.2012.01809.xHon KL, Leung TF, Wong Y, et al. A survey of bathing and showering practices in children with atopic eczema. Clin Exp Dermatol. 2005;30(4):351–354. doi: 10.1111/j.1365-2230.2005.01748.xHon K.L., Leung T.F., Wong Y., et al. A survey of bathing and showering practices in children with atopic eczema // Clin Exp Dermatol. 2005. Vol. 30, N 4. Р. 351–354. doi: 10.1111/j.1365-2230.2005.01748.xWollenberg A, Vogel S, Renner ED. Vaccinations with atopic dermatitis and other chronic inflammatory skin diseases. (In German). Hautarzt. 2010;61(11):985–993. doi: 10.1007/s00105-010-2019-3Wollenberg A., Vogel S., Renner E.D. [Vaccinations with atopic dermatitis and other chronic inflammatory skin diseases. (In German)] // Hautarzt. 2010. Vol. 61, N 11. Р. 985–993. doi: 10.1007/s00105-010-2019-3Bath-Hextall F, Delamere F, Williams H. Dietary exclusions for improving established atopic eczema in adults and children systematic review. Allergy. 2009;64(2):258–264. doi: 10.1111/j.1398-9995.2008.01917.xBath-Hextall F., Delamere F., Williams H. Dietary exclusions for improving established atopic eczema in adults and children systematic review // Allergy. 2009. Vol. 64, N 2. Р. 258–264. doi: 10.1111/j.1398-9995.2008.01917.xNational calendar of preventive vaccinations. Appendix No. 1 to the order of the Ministry of Health of the Russian Federation of March 21, 2014. No. 125n. (In Russ). Available from: https://base.garant.ru/70647158/53f89421bbdaf741eb2d1ecc4ddb4c33/. Accessed: December 15, 2020.Национальный календарь профилактических прививок. Приложение N 1 к приказу Министерства здравоохранения РФ от 21 марта 2014 г. N 125н. Режим доступа: https://base.garant.ru/70647158/53f89421bbdaf741eb2d1ecc4ddb4c33/. Дата обращения: 15.12.2020.Allergology and immunology: national guidelines. Ed. by R.M. Khaitov, N.I. Ilyina. Moscow: GEOTAR-Media; 2009. 634 p. (In Russ).Аллергология и иммунология: национальное руководство / под ред. Р.М. Хаитова, Н.И. Ильиной. Москва: ГЭОТАР-Медиа, 2009. 634 с.Campana R, Dzoro S, Mittermann I, et al. Molecular aspects of allergens in atopic dermatitis. Curr Opin Allergy Clin Immunol. 2017;17(4):269–277. doi: 10.1097/ACI.0000000000000378Campana R., Dzoro S., Mittermann I., et al. Molecular aspects of allergens in atopic dermatitis // Curr Opin Allergy Clin Immunol. 2017. Vol. 17, N 4. P. 269–277. doi: 10.1097/ACI.0000000000000378Cartledge N, Chan S. Atopic Dermatitis and food allergy: a paediatric approach. Curr Pediatr Rev. 2018;14(3):171–179. doi: 10.2174/1573396314666180613083616Cartledge N., Chan S. Atopic Dermatitis and food allergy: a paediatric approach // Curr Pediatr Rev. 2018. Vol. 14, N 3. P. 171–179. doi: 10.2174/1573396314666180613083616Darsow U, Laifaoui J, Kerschenlohr K, et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: A European multicenter study. Allergy. 2004;59(12):1318–1325. doi: 10.1111/j.1398-9995.2004.00556.xDarsow U., Laifaoui J., Kerschenlohr K., et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: A European multicenter study // Allergy. 2004. Vol. 59, N 12. Р. 1318–1325. doi: 10.1111/j.1398-9995.2004.00556.xTamagawa-Mineoka R, Katoh N. Atopic dermatitis: identification and management of complicating factors. Int J Mol Sci. 2020;21(8):2671. doi: 10.3390/ijms21082671Tamagawa-Mineoka R, Katoh N. Atopic dermatitis: identification and management of complicating factors // Int J Mol Sci. 2020. Vol. 21, N 8. Р. 2671. doi: 10.3390/ijms21082671Werfel T, Heratizadeh A, Niebuhr M, et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol. 2015;136(1):96–103.e9. doi: 10.1016/j.jaci.2015.04.015Werfel T., Heratizadeh A., Niebuhr M., et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber // J Allergy Clin Immunol. 2015. Vol. 136, N 1. Р. 96–103.e9. doi: 10.1016/j.jaci.2015.04.015Caut C, Leach M, Steel A. Dietary guideline adherence during preconception and pregnancy: A systematic review. Matern Child Nutr. 2020;16(2):e12916. doi: 10.1111/mcn.12916Caut C., Leach M., Steel A. Dietary guideline adherence during preconception and pregnancy: A systematic review // Matern Child Nutr. 2020. Vol. 16, N 2. P. e12916. doi: 10.1111/mcn.12916Sugita K, Akdis CA. Recent developments and advances in atopic dermatitis and food allergy. Allergol Int. 2020;69(2):204–214. doi: 10.1016/j.alit.2019.08.013Sugita K., Akdis C.A. Recent developments and advances in atopic dermatitis and food allergy // Allergol Int. 2020. Vol. 69, N 2. P. 204-214. doi: 10.1016/j.alit.2019.08.013Fedenko E, Elisyutina O, Shtyrbul O, et al. Microarray-based IgE serology improves management of severe atopic dermatitis in two children. Pediatr Allergy Immunol. 2016;27(6):645–649. doi: 10.1111/pai.12572Fedenko E., Elisyutina O., Shtyrbul O., et al. Microarray-based IgE serology improves management of severe atopic dermatitis in two children // Pediatr Allergy Immunol. 2016. Vol. 27, N 6. P. 645–649. doi: 10.1111/pai.12572Alexander DD, Cabana MD. Partially hydrolyzed 100% whey protein infant formula and reduced risk of atopic dermatitis: a meta-analysis. J Pediatr Gastroenterol Nutr. 2010;50(4):422–430.Alexander D.D., Cabana M.D. Partially hydrolyzed 100% whey protein infant formula and reduced risk of atopic dermatitis: a meta-analysis // J Pediatr Gastroenterol Nutr. 2010. Vol. 50, N 4. P. 422–430.Niggemann B, Reibel S, Wahn U. The atopy patch test (APT)–a useful tool for the diagnosis of food allergy in children with atopic dermatitis. Allergy. 2000;55(3):281–285.Niggemann B., Reibel S., Wahn U. The atopy patch test (APT) ― a useful tool for the diagnosis of food allergy in children with atopic dermatitis // Allergy. 2000. Vol. 55, N 3. P. 281–285.Sampson HA, Albergo R. Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis. J Allergy Clin Immunol. 1984;74(1):26–33.Sampson H.A., Albergo R. Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis // J Allergy Clin Immunol. 1984. Vol. 74, N 1. P. 26–33.Roehr CC, Reibel S, Ziegert M, et al. Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis. J Allergy Clin Immunol. 2001;107(3):548–553. doi: 10.1067/mai.2001.112849Roehr C.C., Reibel S., Ziegert M., et al. Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis // J Allergy Clin Immunol. 2001. Vol. 107, N 3. P. 548–553. doi: 10.1067/mai.2001.112849